Table of contents :

bone marrow

Blood / haema / hema / sanguis : the fluid that circulates through the heart, arteries, capillaries, and veins, carrying nutriment and oxygen to the body cells. It consists of the plasma, a pale yellow liquid containing the microscopically visible formed elements of the blood: the erythrocytes, or red blood corpuscles; the leukocytes, or white blood corpuscles; and the platelets, or thrombocytes. Its amount in a normal adult is ~ 5 L (~ 7% of body volume or 8.5-9.0% of body mass) :

• arterial blood : oxygenated blood, found in the pulmonary veins, the left chambers of the heart, and the systemic arteries; it is bright red in color
• venous blood : deoxygenated blood, found in the systemic veins, the right chambers of the heart, and the pulmonary arteries; it is dark red in color.
• cord blood : blood contained within the umbilical vessels at the time of delivery of the infant.
• peripheral blood : blood obtained from acral areas, or from the circulation remote from the heart, as from earlobe, fingertip, or heel pad (in a child), or from the antecubital vein; the blood in the systemic circulation.
• whole human blood : blood from which none of the elements have been removed.  2. blood that has been drawn from a selected donor under strict aseptic conditions, containing citrate ion or heparin as an anticoagulant; used as a blood replenisher
• citrated blood : blood treated with sodium citrate or citric acid to prevent its coagulation.
• defibrinated blood : whole blood from which fibrin was separated during the clotting process.
• laky blood : blood that has undergone laking and contains at least some lysed erythrocytes.
• occult blood : blood present in such small quantities that, while it is not visible to the naked eye, it can be detected only by chemical tests of suspected material, e.g., feces.
• sludged blood : blood in which the red cells have become aggregated into masses

• blood islands : aggregations of mesenchyme cells in the angioblast of the early embryo, as in the wall of the yolk sac; they subsequently develop into vascular endothelium and blood corpuscles.
• 40-45 % is represented by figurated elements (cells and platelets) arising from hematopoiesis :
• primitive hematopoiesis (only erythrocytes and megakaryocytes are produced) :
• from foetal week ? up to foetal week 12 in yolk sac (and intraembryonic splanchnopleura ?)
• definitive hematopoiesis from (pluripotent) hematopoietic stem cell ((P)HSC)
• from foetal week ? up to foetal week ? in aorta-gonads-mesonephros (AGM) region (HSCs are probably generated within the layer of endothelial cells that lines the wall of the dorsal aorta, so sharing a common precursor with endothelial cells)
• from foetal week 6 up to foetal week 38 in liver
• from foetal week 12 up to foetal week 38 in spleen and lymph nodes
• from foetal week 20 up in bone marrow, decreasing with age (in long bones no hematopoiesis occur after age 20, except for the proximal portion of humeruses and tibias => only in flat bones (vertebrae, sternum, ribs and iliac wings)). Each day an adult produces approximately 200 billion erythrocytes (3 x 10⁹/kg), 100 billion leukocytes (0.8 x 10⁹/kg) , and 100 billion platelets (1.5 x 10⁹/kg). Moreover, these rates can increase by a factor or 10 or more when the demand for blood cells increases.

HSC localization to the bone marrow depends on CXCL12 / SDF-1 (produced by bone marrow stromal cells)-- CXCR4 interaction. The bone marrow microenvironment has a crucial supporting role in the growth, differentiation and survival of HSC. Without bone-marrow stromal cells, HSCs cannot be maintained in vitro, even when cultured with a cocktail of growth factors. KIRRE / NEPH2 protein is accumulated in the areas of contact to maintain HSCs in an undifferentiated, proliferative state. TIE1 and TIE2 receptor tyrosine kinases are not required for fetal haematopoiesis, but they are requried during postnatal bone-marrow hematopoiesis^ref. Unique features of bone that contribute to a microenvironmental niche for stem cells might include the known high concentration of calcium ions at the HSC-enriched endosteal surface. Cells respond to extracellular ionic calcium concentrations through calcium-sensing receptor (CaSR), expressed on HSCs. Through the CaSR, the simple ionic mineral content of the niche may dictate the preferential localization of adult mammalian haematopoiesis in bone. Antenatal mice deficient in CaSR had primitive haematopoietic cells in the circulation and spleen, whereas few were found in bone marrow. CaSR^-/- HSCs from fetal liver were normal in number, in proliferative and differentiative function, and in migration and homing to the bone marrow. Yet they were highly defective in localizing anatomically to the endosteal niche, behaviour that correlated with defective adhesion to the extracellular matrix protein, collagen I. CaSR has a function in retaining HSCs in close physical proximity to the endosteal surface and the regulatory niche components associated with it^ref. HSCs can be isolated efficiently from bone marrow cells by following Gata2-directed GFP fluorescence, and that they can also be monitored in vivo. Each individual GFP⁺ cell lay in a G₀/G₁ cell cycle state, in intimate contact with osteoblasts beside the endosteum, at the edge of the bone marrow. The HSC niche is composed of solitary cells and that adult bone marrow HSC are not clustered^ref
• diseases that cause bone marrow replacement can cause hematopoiesis to revert to the liver, even in adulthood.
Normal myelogram in adulthood :
• granulocyte series (56%)
• myeloblast (1.0%)
• promyelocyte (3.4%)
• myelocyte (11.9%)
• metamyelocyte (18%)
• band form (11%)
• neutrophils (10.7%)
• eosinophils (3.2%)
• basophils (< 0.1%)
• erythroid series (21.5%)
• proerythroblast (0.6%)
• basophilic erythroblast (2.0%)
• polychromatophilic erythroblast (12.4%)
• orthochromatic erythroblast (6.5%)
• megakaryocytes (< 0.1%)
• lymphocytes (15.8%)
• plasma cells (1.8%)
• monocytes (1.8%)
The initial divisions of HSC are likely to involve cytokine-independent stochastic fate choices (promiscuous gene expression provides a framework for stochastic fluctuations in expression of signaling or transcriptional complexes, which ultimately are amplified or repressed to cement lineage choice), while maturation of terminally differentiated cells from progenitor and precursor cells depends on instructive cytokines.
• colony-forming unit (CFU) : any of several hematopoietic stem cells identified by their ability to give rise to monoclonal colonies in the spleen when transplanted into isogeneic, lethally irradiated mice.
• unitarian or monophyletic theory / monophyletism : the theory that all forms of blood cells have their origin in a single type of cell, the blast cell / hematoblast / hematocytoblast / hemoblast / hemocytoblast / hematogone / hematohistioblast / hemohistioblast (which develops into a pluripotential stem cell), with the different types of cells arising from there by a process of differentiation


• polyphyletic theory / polyphyletism : the theory that the various blood cells have their origin from two or more types of stem cells
• dualistic theory / dualism : a variant of the polyphyletic theory that holds that blood cells arise from 2 distinct types of stem cells, the myeloblasts and lymphoblasts
• trialistic theory / trialism : a variant of the polyphyletic theory that holds that blood cells arise from 3 distinct types of stem cells, the myeloblasts, lymphoblasts, and monocytes
Hematopoietins at COPE
• synclitism / syncliticism : normal, synchronous maturation of the nucleus and cytoplasm of blood cells
IL-3, SCF and EPO induce expression of the anti-apoptotic protein anamorsin, essential for late stages of definitive hematopoiesis and terminal differentiation (deficient embryos die in late gestation due to anemia with reduces by 50% the number of peripheral RBCs compared with littermate controls, and a marked proportion of cells in the fetal liver, which was < 1/3 of the size of that in anamorsin-sufficient embryos, are apoptotic)^ref
MicroRNAs (miRNAs) influence hematopoietic lineage commitment but do not completely block differentiation to other lineages : in mouse 3 miRNAs show preferential expression in haematopoietic tissue^ref
• miR-142 is most highly expressed by B cells and myeloid cells
• miR-181 is preferentialy expressed by the B-lymphoid lineage compared with undifferentiated progenitor cells or other lineages
• miR-223 is preferentially expressed by myeloid lineage cells

[a viral homologue of  CD200 encoded by the K14 ORF of HHV8 interacts with the CD200R with the same kinetics and low affinity as the host protein, although it has only 40% sequence identity. Cells expressing CD200 or K14 inhibits the secretion of pro-inflammatory cytokines by activated macrophages, indicating that infected cells might deliver downmodulatory signals to host myeloid cells through the CD200 receptor to evade elimination^ref]

Ape1 is required in normal embryonic hematopoiesis and that the redox, but not the repair endonuclease function of Ape1 is critical in normal embryonic hematopoietic development^ref. Promoter polymorphisms between C57BL/6 (B6) and DBA/2 (D2) mice alleles may affect latexin (Lxn) gene expression and consequently influence the population size of hematopoietic stem cells^ref.

early progenitors with lymphoid and myeloid potential (EPLM) CD19^– B220⁺CD117^lowCD135 / Flt⁺. Treatment of mice with the corresponding ligand, Flt3L, showed a 50-fold increase in EPLM. In addition to the expected increase in DC numbers, Flt3L treatment had a reversible inhibitory effect on B lymphopoiesis. Limiting dilution analysis of sorted EPLM from Flt3L-treated mice showed that B-lymphocyte progenitor activity was reduced 20-fold, but that myeloid and T-cell progenitor activity was largely preserved. EPLM from treated mice transiently reconstituted the thymus and bone marrow of recipient mice, generating cohorts of functional T and B cells in peripheral lymphoid organs. Thus, Flt3L treatment results in a dramatic increase in a novel bone marrow cell with lymphoid and myeloid progenitor activity^ref.
 

+ ? :
• precursor of myeloid cells (p-M)

+ ? :
• common myeloerythroid progenitor (p-ME)
‡
+ SCF, IL-1b, IL-3, IL-4, IL-6 :
• MEMeg
• erythroid cells => erythropoiesis: the erythron is found near bone marrow blood vessels and its maturation requires ~ 5 days. Functional reserve allows increasing output by 6-8 folds. Uneffective erythropoiesis normally accounts for 10-15%. It consists of :
• burst-forming unit–erythroid (P-BFU-E) : the earliest erythrocyte precursor in the erythrocytic series, detectable mainly in vitro and having a high requirement for Epo; it gets its name from the fact that its growth is composed of subcolonies resembling bursts

‡
+ GM-CSF, IL-1b, IL-3, IL-4; need GATA1 : the hypomorphic Gata1^low mutation increases the proliferation potential of a unique class of progenitor cells, similar in phenotype to adult common erythroid/megakaryocytic progenitors (MEP), but with the "unique" capacity to generate erythroblasts, megakaryocytes and mast cells in vitro. Conversely, progenitor cells phenotypically similar to mast cell progenitors (MCP) are not detectable in the marrow from these mutants. At the single cell level, ~11% of Gata1^low progenitor cells, including MEP, generate cells that will continue to proliferate in cultures for up to 4 months. In agreement with these results, tri-lineage (erythroid, megakaryocytic and mastocytic) cell lines are consistently isolated from bone marrow and spleen cells of Gata1^low mice^ref
• M-BFU-E (EPOR⁺laminin receptor p67^+ref)

‡
• colony-forming unit–erythroid (CFU-E) : an erythrocyte precursor in the erythrocyte series that follows the burst-forming unit–erythroid and precedes the proerythroblast; detectable mainly in vitro (CD71 / TfR⁺EPOR⁺⁺)

‡
+ Epo, IL-9 :
• nucleated RBC (NRBC)
• proerythroblast / pronormoblast / lymphoid hemoblast of Pappenheim / rubriblast (CD71 / TfR⁺235a / glycophorin A^-235b / glycophorin B^-235R / glycophorin C^-) : 20-25 mm diameter; basophilic cytoplasm with large, distinct nucleoli


They begin synthesis of hemoglobins (Hb), the red oxygen-carrying pigment of erythrocytes, formed by developing erythrocytes in bone marrow. It is a type of hemoprotein that contains 4 heme groups and globin and has the property of reversible oxygenation. A molecule of hemoglobin contains 4 polypeptide globin chains, composed of between 141 and 146 amino acids; those most often found are a and b chains, with g and d chains seen somewhat less often. Different types of hemoglobins are determined by different combinations of chains, with the number of chains of each type in the molecule being indicated by a subscript. Hundreds of hemoglobins with differing electrophoretic mobilities and characteristics have been reported; the first ones were given capital letters, such as S, C, D, E, G, H, I, J, K, L, M, N, and Q. As refined biochemical techniques led to the discovery of many additional hemoglobins, newer standards for nomenclature were devised: those with electrophoretic mobility equal to one of the lettered hemoglobins could be named with that letter using the place of discovery as a subscript, such as hemoglobin M_Saskatoon or hemoglobin M_Milwaukee. New hemoglobins with unique electrophoretic mobilities are now often named simply for the laboratory, hospital, or town where they were discovered, such as hemoglobin Chesapeake or hemoglobin Gun Hill. When known, the number of each amino acid substituting in each polypeptide in the molecule should be indicated by the appropriate superscript numeral
• 4 chains of globin(s) (synthetized in cytoplasm)
• globins genes are arranged as follows :
• on chromosome 16p13.3 : 5'-z-y_z-y_a2-y_a1-a₂-a₁-q₁-3'. a₂ and a₁ cds are identical but genes differ in 5'UTR, intron, and 3'UTR


• on chromosome 11p15.5 : 5'-e-g_G-g_A-y_b-d-b-3'
• the chicken embryonic b-type globin gene, r, is a member of a small group of vertebrate genes whose developmentally regulated expression is mediated by DNA methylation. A methylcytosine binding complex binds to the methylated r-globin gene in vitro. 4 components of the MeCP1 transcriptional repression complex were identified: MBD2, RBAP48, HDAC2 and MTA1. These 4 proteins, as well as the zinc-finger protein p66 and the chromatin remodeling factor Mi2, were found to coelute by gel-filtration analysis and pull-down assays. These 6 proteins are components of the MeCPC. In adult erythrocytes, significant enrichment for MBD2 is seen at the inactive r-globin gene by chromatin immunoprecipitation assay, whereas no enrichment is observed at the active A-globin gene, demonstrating MBD2 binds to the methylated and transcriptionally silent -globin gene in vivo. Knock-down of MBD2 resulted in upregulation of a methylated r-gene contruct in MEL-r cells. These results represent the first purification of a MeCP1-like complex from a primary cell source and provide support for a role for MBD2 in developmental gene regulation^ref.
• in embryo :
• Gower hemoglobin / hemoglobin Gower : present in early embryonic life and disappearing before birth
• Hb Gower-1 (z₂e₂)
• Hb Gower-2 (a₂e₂)
• occasionally e₄
• in fetus :
• HbF / fetal hemoglobin (a₂g₂^F) : > 50%;becomes the dominant fetal hemoglobin at 2 months' gestation. HbF binds oxygen more tightly than HbA, enhancing delivery of oxygen from maternal oxyhemoglobin to fetal deoxyhemoglobin at the placenta.
• Hb Portland (z₂g₂) present in the fetus late in the first trimester of pregnancy; it disappears in utero.
• HbA₂ (a₂d₂)
• in adults : KLF1 / EKLF and PYR complex modulate a shift from g- to b-globin binding to the b-globin promoter but not to the repeated CCTTG domain in the g-globin promoter.
• HbA (a₂^Ab₂^A or a₂b₂) (97%)
• HbA₀ (93-95%)
• HbA₁ / glycated hemoglobin (GHb) / glycohemoglobin (5-7%) (sometimes unproperly^ref named glycosylated or glucosylated haemoglobin) (3.9-6.1%) : any of various hemoglobins to which glucose is bound by glycation.
• HbA_1a (0.5%)
• HbA_1b (0.5%)
• HbA_1c (4-6%) has a hexose attached to the N terminal of its b chain. HbA_1c is formed through the progressive glycosylation of Hb during the 120-day lifetime of erythrocytes^ref. It forms when haemoglobin is exposed to glucose and undergoes a sequence of nonenzymatic reactions. The first is the rapid but reversible formation of an aldimine (or Schiff base), followed by the considerably slower formation of a stable ketoamine via a process known as the Amadori rearrangement^ref. The ketoamine steadily accumulates over the life of the red cell and forms the bulk of the glycated haemoglobin measured by laboratories. Therefore, both the erythrocyte age and blood glucose concentration are important determinants of the HbA_1c value. Young erythrocytes have lower HbA_1c values than old; its levels are increased in poorly controlled diabetes mellitus
• HbA₂ (a₂^Ad₂^A2 or a₂^Ad₂) (1.5-3%)
• HbF (a₂g₂) (0.5-2%) : abnormally elevated in aplastic anemia, leukemia, and certain types of thalassemia

Coordinated expression of the genes in each cluster at all stages of development is dependent on critical regulatory elements located upstream of the genes. In the ß cluster there are 5 such elements, collectively referred to as the locus control region (LCR) while in the a cluster, there is a single known element referred to as HS-40. In normal individuals, the synthesis of a and ß globin chains is finely balanced during terminal erythroid differentiation, giving rise to red cells of consistent size (MCV) and hemoglobin content (MCH).
The synthesis of haemoglobin A (HbA) is exquisitely coordinated during erythrocyte development to prevent damaging effects from individual a- and b-subunits. The a-haemoglobin-stabilizing protein (AHSP) / erythroid associated factor (ERAF) binds a-haemoglobin (aHb), inhibits the ability of aHb to generate reactive oxygen species and prevents its precipitation on exposure to oxidant stress. The structure of AHSP bound to ferrous aHb is thought to represent a transitional complex through which aHb is converted to a non-reactive, hexacoordinate ferric form. The crystal structure of this ferric aHb-AHSP complex has been reported at 2.4 Å resolution. There is a striking bis-histidyl configuration in which both the proximal and the distal histidines coordinate the haem iron atom. To attain this unusual conformation, segments of aHb undergo drastic structural rearrangements, including the repositioning of several a-helices. Moreover, conversion to the ferric bis-histidine configuration strongly and specifically inhibits redox chemistry catalysis and haem loss from aHb. The observed structural changes, which impair the chemical reactivity of haem iron, explain how AHSP stabilizes aHb and prevents its damaging effects in cells^ref.
Function of globins :
• prevent Fe²⁺ oxidation by carried O₂
• blood pH buffering
• 4 heme molecules (one per globin), synthetized in mitochondrial matrix and cytoplasm in the following steps :
• glycine + succinyl-CoA

‡
• a-amino-b-ketoadipic acid

‡
• d-aminolevulinic acid :

‡ porphobilinogen synthase / aminolevulinate dehydratase : The enzyme is inhibited by minute quantities of lead poisoning. Genetic deficiency of the enzyme causes a porphyria similar to acute intermittent porphyria but with high urinary levels of d-aminolevulinic acid, coproporphyrinogen III, and protoporphyrin but not porphobilinogen. It is an enzyme of the lyase class that catalyzes the condensation of 2 molecules of d-aminolevulinate to form ...
• porphobilinogen (PBG) : the immediate precursor of the porphyrins, a pyrrole ring with acetyl, propionyl, and aminomethyl side chains; 4 molecules of porphobilinogen are condensed to form one molecule of uroporphyrinogen III, which is then converted successively to coproporphyrinogen III, protoporphyrin IX, and heme. Porphobilinogen is produced in excess and excreted in the urine in acute intermittent porphyria and several other porphyrias

‡
• porphyrinogen : the reduced form of a porphyrin, containing pyrrole rings linked by methylene (—CH₂—) instead of methylidyne bridges. The porphyrinogen forms are the functional intermediates in the biosynthesis of heme and if oxidized to their corresponding porphyrins, such as occurs in porphyrias, are irreversibly removed from the biosynthetic pathway and accumulate in tissues. Their nomenclature corresponds to that of the porphyrins.
‡
• porphyrin : any of a group of compounds containing the porphin structure, four pyrrole rings connected by methylidyne (—CH=) bridges in a cyclic configuration, to which a variety of side chains may be attached. The nature of the side chains is indicated by a prefix, such as coproporphyrin, deuteroporphyrin, etioporphyrin (each pyrrole ring has one methyl and one ethyl side chain), hematoporphyrin (2 pyrrole rings have 1 methyl and 1 propionate side chain and the other 2 pyrrole rings have 1 methyl and 1 1-hydroxyethyl side chain), mesoporphyrin (2 pyrrole rings each have 1 methyl and 1 propionate side chain and the other 2 pyrrole rings each have 1 methyl and 1 ethyl side chain), protoporphyrin, or uroporphyrin.. Structural isomers are indicated by roman numerals. Free porphyrins are rarely found in tissues except in disorders of heme biosynthesis (porphyrias), but they do occur in the prosthetic groups of hemoglobin, myoglobin, and cytochromes, complexed with metal ions. The term is sometimes used to include porphin or to denote porphin specifically


(A) : pyrrole ring; (B) : porphin ring; (C) : protoporphyrin IX.
• porphyrinogen : the reduced form of a porphyrin, containing pyrrole rings linked by methylene (—CH₂—) instead of methylidyne bridges. The porphyrinogen forms are the functional intermediates in the biosynthesis of heme and if oxidized to their corresponding porphyrins, such as occurs in porphyrias, are irreversibly removed from the biosynthetic pathway and accumulate in tissues. Their nomenclature corresponds to that of the porphyrins

‡
• uroporphyrinogen : a porphyrinogen in which each pyrrole ring has one acetate side chain and one propionate side chain; it is formed by condensation of 4 molecules of porphobilinogen. 4 isomers are possible but only 2 exist naturally, types I and III; the latter is a functional intermediate in heme biosynthesis while the former is produced in an abortive side reaction.

‡
• uroporphyrin : the porphyrin produced by oxidation of the methylene bridges in uroporphyrinogen. Excessive amounts of uroporphyrin I are excreted in congenital erythropoietic porphyria, and both types I and III are excreted in porphyria cutanea tarda
• coproporphyrinogen : a porphyrinogen in which each pyrrole ring has one methyl side chain and one propionate side chain; it is formed by oxidative decarboxylation of uroporphyrinogen. 4 isomers are possible but only 2 exist naturally, types I and III; the latter is a functional intermediate in heme biosynthesis while the former is produced in an abortive side reaction.

‡
• coproporphyrin : the porphyrin produced by oxidation of the methylene bridges in coproporphyrinogen. Coproporphyrin III is excreted in the feces and urine in hereditary coproporphyria and in variegate porphyria, particularly during acute attacks; coproporphyrin I is excreted in the feces and urine in congenital erythropoietic porphyria
• harderoporphyrin : an intermediate in heme biosynthesis, formed in the conversion of coproporphyrinogen to protoporphyrinogen and excreted excessively in the feces in harderoporphyria

‡
• protoporphyrinogen : a porphyrinogen in which 2 pyrrole rings each have one methyl and one propionate side chain and the other two pyrrole rings each have one methyl and one vinyl side chain. 15 isomers are possible but only one, type IX, occurs naturally, produced by oxidative decarboxylation of coproporphyrinogen; it is an intermediate in heme biosynthesis.

‡
• protoporphyrin : the porphyrin produced by oxidation of the methylene bridge of protoporphyrinogen. Protoporphyrin IX is the only naturally occurring isomer; it is an intermediate in heme biosynthesis, combining with ferrous iron to form protoheme IX, the heme prosthetic group of hemoglobin. It is accumulated and excreted excessively in the feces in protoporphyria and variegate porphyria
• free erythrocyte protoporphyrin (FEP) : protoporphyrin free in the blood rather than incorporated into erythrocytes; most is actually bound to zinc as zinc protoporphyrin. The amount increases greatly in iron-deficiency anemia, lead poisoning, and protoporphyria
• zinc protoporphyrin : free erythrocyte protoporphyrin that is bound to zinc.
• protoporphyrin IX, which binds to ... :
• Fe²⁺ : erythroblasts must modify the "standard" post-transcriptional feedback regulation, balancing expression of ferritin (iron storage) versus TfR1 (iron uptake) via specific mRNA binding of iron regulatory proteins (IRPs) (IRP-1 / aconitase and IRP2). Although erythroid differentiation involves high levels of incoming iron, TfR1 mRNA stability must be sustained and Fer mRNA translation must not be activated because iron storage would counteract hemoglobinization. Furthermore, translation of the erythroid-specific form of aminolevulinic acid synthase (ALAS-E) mRNA, catalyzing the first step of heme biosynthesis and regulated similarly as Fer mRNA by IRPs, must be ensured. Strong inhibition of Fer mRNA translation and efficient ALAS-E mRNA translation in differentiating erythroblasts Moreover, in contrast to self-renewing cells, TfR1 stability and IRP mRNA binding were no longer modulated by iron supply^ref
After ABCB6 is upregulated in response to increased intracellular porphyrin, mitochondrial porphyrin uptake activates de novo porphyrin biosynthesis^ref.
Each hemoglobin molecule can bind 4 O₂ molecules. Each gram of hemoglobin can bind 1.39 mL O₂. Without such a buffering, plasma could carry only 0.29 mL O₂ / dL.
Oxygen-hemoglobin dissociation curves : a graphic curve representing the normal variation in the amount of O₂ that combines with hemoglobin (oxidized or oxygenated hemoglobin / oxyhemoglobin = 1 - reduced hemoglobin / deoxyhemoglobin) as a function of the partial pressure of oxygen (P_O2)

• shift to the right (the Bohr effect) when less than a normal amount of oxygen is taken up by the blood at a given P_O2
• decreased pH, increased temperature and increased P_CO2, such as occur in the capillaries in metabolically active tissue
• increased concentration of 2,3-DPG
• presence of carbon monoxide
• certain disease states
• shift to the left (the Haldane effect) when more than a normal amount is taken up.
• increased pH, decreased temperature and decreased P_CO2, such as occurs in the alveolar capillaries of the lungs
• decreased 2,3-DPG concentration
It is proposed that the bond between nitric oxide (NO) and the Hb thiol Cys-b⁹³ (SNOHb) is favored when hemoglobin (Hb) is in the relaxed (R, oxygenated) conformation, and that deoxygenation to tense (T) state destabilizes the SNOHb bond, allowing transfer of NO from Hb to form other (vasoactive) S-nitrosothiols (SNOs). However, it has not previously been possible to measure SNOHb without extensive Hb preparation, altering its allostery and SNO distribution. An assay for SNOHb that uses carbon monoxide (CO) and cuprous chloride (CuCl)-saturated Cys is specific for SNOs and sensitive to 2–5 pmol. Uniquely, it measures the total SNO content of unmodified erythrocytes (RBCs) (SNO_RBC), preserving Hb allostery. In room air, the ratio of SNO_RBC to Hb in intact RBCs is stable over time, but there is a logarithmic loss of SNO_RBC with oxyHb desaturation (slope, 0.043). This decay is accelerated by extraerythrocytic thiol (slope, 0.089; P < 0.001). SNO_RBC stability is uncoupled from O₂ tension when Hb is locked in the R state by CO pretreatment. Also, SNO_RBC is increased 20-fold in human septic shock (P = 0.002) and the O₂-dependent vasoactivity of RBCs is affected profoundly by SNO content in a murine lung bioassay. These data demonstrate that SNO content and O₂ saturation are tightly coupled in intact RBCs and that this coupling is likely to be of pathophysiological significance^ref.
‡
• basophilic erythroblast / basophilic normoblast / prorubricyte (CD71 / TfR⁺235a / glycophorin A⁺235b / glycophorin B⁺235R / glycophorin C⁺). 16-18 mm diameter; The cytoplasm is intensely basophilic; indistinct nucleoli. As the cell matures, chromatin condensation or "clumping" becomes more prominent.

In adult bone marrow, mature erythroblasts are produced within structures called erythroblastic islands and then cross the endothelial barrier to reach circulation. Erythroblastic islands are composed of a central macrophage surrounded by maturing erythroblasts. Erythroid cells, but not the other mature hematopoietic cells, coexpress 2 angiogenic factors, VEGF-A and PlGF. Secretion of both VEGF-A and PlGF increases during in vitro erythroid differentiation. Erythroblast-conditioned medium can induce both migration of monocytes and endothelial cells and the permeability of endothelial cells. These effects are inhibited by anti-PlGF and/or anti-VEGF antibodies. Finally, it is shown that VEGF-A and PlGF proteins are expressed by bone marrow erythroblasts in vivo. Angiogenic factors secreted by erythroblasts may promote interactions either with macrophages in erythroblastic islands or with endothelial cells that would facilitate the passage of erythroid cells through the endothelial barrier^ref. The nonclassical HLA-G class I molecule is secreted by both primitive erythroid cells of the yolk sac and endothelial cells from developing vessels. Moreover, HLA-G is present in its soluble form in the erythropoietic lineage in all organs sustaining primitive to definitive erythropoiesis (ie, aorta-gonad-mesonephros, liver, spleen, and bone marrow). The alternatively spliced transcript coding the soluble HLA-G5 molecule was detected in erythroid cells. The corresponding intron 4-retaining 37-kDa HLA-G5 isoform was secreted from the erythroid progenitor stage to the reticulocyte but was lost in mature erythrocytes and in endothelial cells from differentiated vessels^ref.

‡
• polychromatic or polychromatophil erythroblast or normoblast / rubricyte : immature erythrocytes 12-15 mm diameter staining with both acid and basic stains so that their color is a diffuse mixture of blue-gray and pink (CD71 / TfR⁺)


‡
• orthochromatic (i.e. acidophilic) erythroblast or normoblast / metarubricyte (CD71 / TfR⁺) : 9-11 mm diameter; pyknotic nucleus


‡
• up-regulation of survivin^ref
• cell-cycle exit and nucleus exocytosis (enucleation) : definitive erythropoiesis usually occurs in the bone marrow or fetal liver, where erythroblasts are associated with a central macrophage in anatomical units called 'blood islands'. Late in erythropoiesis, nuclei are expelled from the erythroid precursor cells and engulfed by the macrophages in the blood island. The nuclei are engulfed by macrophages only after they are disconnected from reticulocytes, and that phosphatidylserine, which is often used as an 'eat me' signal for apoptotic cells, is also used for the engulfment of nuclei expelled from erythroblasts. When late-stage erythroblasts from the spleens of phlebotomized mice were cultured, the nuclei protruded spontaneously from the erythroblasts. A weak physical force could disconnect the nuclei from the reticulocytes. The released nuclei contained an undetectable level of ATP, and quickly exposed phosphatidylserine on their surface. Fetal liver macrophages efficiently engulfed the nuclei; masking the phosphatidylserine on the nuclei with the dominant-negative form of milk-fat-globule EGF8 (MFG-E8) prevented this engulfment^ref
• adult red blood cells have no mitochondria : the cells have no Krebs cycle and meet their energy requirements by glycolysis
• reticulocyte (CD71 / TfR⁺) circulates for only 1 to 2 days; 7-9 mm diameter


Using special stains such as methylene blue or brilliant cresyl blue, reticulocytes stain with dark blue granules (mitochondria and cytoplasmid ribonucleoproteins) whereas mature erythrocytes evenly stain pale blue.

• reticulocyte count : 0.5÷1.5% of total blood cells, recorded as ...
• the percentage of the erythrocyte count
• an absolute number absolute reticulocyte count (ARC) = %[reticulocyte] ^. RBC = 35,000÷40,000 / mL
• correction for anemia : %[reticulocyte] ^. (HCT of the patient)/(normal HCT)
• reticulocyte index = %[reticulocyte] ^. (patient's HCT) / (normal HCT) ^. 0.5 = 1-2.5
• > 2.5 : good erythropoietic response to hemolytic anemia
• < 1 : aplastic crisis
It provides a means of assessing the erythropoietic activity of the bone marrow.
‡
• erythrocyte / red blood cell (RBC) / ozonophore (CD14^-15^-35 / CR1⁺46^-47⁺55 / DAF⁺75⁺233 / Diego blood group / band 3⁺234 / Duffy antigen / Fy-glycoprotein⁺235a / glycophorin A⁺235b / glycophorin B⁺235R / glycophorin C⁺238 / Kell⁺241 / Rh Ag⁺carbonic anhydrase I⁺). 7-8 mm diameter; The main function of RBCs is to avoid filtration of 3% hemoglobin into urine.

A model depicting the major proteins of the erythrocyte membrane^ref :

Major erythrocyte membrane proteins :

band	designation	molecular weight	chromosomal locus	function	interactions	localization	associated disease
1	a-spectrin (SPTA1)	281	1q22-q23	membrane skeleton	band 3, ankyrin	peripheral	hereditary elliptocytosis, hereditary pyropoikylocytosis, hereditary spherocytosis
1	b-spectrin (SPTB)	246	14q23-q24.1				hereditary spherocytosis
2.1	ankyrin 1 (ANK1)	206	8p11.2	binds membrane protien and cytoskeleton	band 3, b-spectrin	peripheral
2.9	a-adducin / adductin 1 (ADD1)	81	4p16.3	binds actin filaments	spectrin, b-actin	peripheral
2.9	b-adducin / adducin 2 (ADD2)	80		binds actin filaments	spectrin, b-actin	peripheral
3	SLC4A1 / erythrocyte membrane protein band 3 / anion exchange protein 1 (AE1) / CD233	102	17q12-q21	anion transport	ankyrin, spectrin, protein 4.1	integral	hereditary elliptocytosis, hereditary spherocytosis, Southeast Asian ovalocytosis
4.1	erythrocyte membrane protein band 4.1 (EPB41)	66	1p33-p34.1	membrane skeleton	spectrin, b-actin, GPC	peripheral	hereditary elliptocytosis
4.2	pallidin	77	5q15-q21	binds cytoskeleton to lipid bilayer	band 3, ankyrin	peripheral
4.9	dematin / EPB49 (a, b)	43+46	8p21.2-21.1	actin-binding protein	b-actin, lipids	peripheral
4.9	p55 / MPP1	53	Xq28		protein 4.1, GPC	peripheral
5	b-actin	42	7pter-q22	membrane skeleton	spectrin, protein 4.1	peripheral
5	tropomodulin	41	9q22	blocks growth of actin filaments	tropomyosin, b-actin	peripheral
6	GADPH	36	12q13		band 3	peripheral
7	stomatin	32				integral	hereditary stomatocytosis
7	tropomyosin	28	1q31	stabilization of actin filaments	b-actin	peripheral
8	protein 8	23				peripheral
GPA	glycophorin A (GYPA) / MNS blood group	14	4q31	receptor for Plasmodium falciparum	negatively-charged phospholipids	integral	none
GPB	CD235b / glycophorin B	8	4q31	anchor for membrane skeleton	protein 4.1	integral	none
GPC	CD235R / glycophorin C (GYPC)	14	2q14-q21		protein 4.1, p55	integral	hereditary elliptocytosis
GPD	glycophorin D	11	2q14-q21			integral	hereditary elliptocytosis
GPE	glycophorin E (GYPE)	6	4q31			integral

Normal values :
• erythrocyte or red blood cell count (RBC) (blood that has been diluted in an isotonic solution, done with an automatic counter such as a flow cytometer) = 3^.10⁹RBCs / weight Kg ; 98% of total blood cells
• 4.5÷5.9 ^. 10⁶ RBCs / mL blood in males
• 4.1÷5.1 ^. 10⁶ RBCs / mL blood in females
• average life : 120 days (established with ⁵¹Cr release test).
• hematocrit (HCT) : 42÷50% in males ; 36÷45% in females
• microhematocrit : a hematocrit determination done on an extremely small quantity of blood, by use of a capillary tube and a high speed centrifuge.
• hemoglobin (HGB) : 13÷17.5 g / dL whole blood in males, 12÷15.5 g / dL in females. So 21 (in males) or 19 (in females) mL of O₂ can be bound for every dL of whole blood.
• hemoglobin distribution width (HDW) : 2.3÷3.2 g / dL whole blood
• red blood cell or erythrocyte indices :
• mean corpuscular volume (MCV) : 10 ^. HCT / RBC = 80÷95 fL=mm³
• mean corpuscular hemoglobin (MCH) : 10 ^. HGB / RBC = 27.5÷33 pg per red cell
• mean corpuscular hemoglobin concentration (MCHC) (assuming plasma hemoglobin is very low) : 100 ^. HGB / HCT = 33÷35 g / dL RBC (~ 34 % ^v/_v)
• RBC distribution width (RDW)
• Price-Jones curve : a frequency distribution curve of erythrocyte diameters, calculated electronically with a Coulter counter, a flow cytometer, or a similar instrument; it can detect conditions such as macrocytic anemia and microcytic anemia
• standard deviation (SD) : width of the distribution curve when frequency = 20% : 38.7÷45.1 fL=mm³
• coefficient of variation (CV) : 100 ^. SD / MCV = 11.5÷14.5 %
• volume of red blood cells (VRBC) is used routinely in the diagnostic work-up of polycythemia, in assessing the efficacy of erythropoietin administration, and to study factors affecting oxygen transport. VRBC, ⁵¹Cr and MHb, CO are the best measures for research on blood-related changes in oxygen transport. With care, VRBC, Evans is suitable for clinical applications of blood-volume measurement. Techniques based on^ref :
• Evans blue (VRBC, Evans)
• ⁵¹chromium-labelled red cells (VRBC, ⁵¹Cr)
• carbon-monoxide rebreathing (VRBC, CO)
• hemoglobin mass with the carbon-monoxide method (MHb, CO)
• erythrocyte sedimentation rate (ESR) of whole blood + anticoagulant : the rate at which erythrocytes precipitate out from a well-mixed specimen of venous blood, measured by the distance the top of the column of erythrocytes falls in a given time interval under specified conditions. The traditional methods of calculating ESR are the :

	males	females
Wintrobe method : EDTA-anticoagulated whole blood is placed in a Wintrobe hematocrit tube	1-13 mm / hr	1-20 mm / hr
Westergren method (the most common method) : 4 volumes of whole blood are mixed with 1 volume of sodium citrate anticoagulant-diluent solution and placed in a Westergren tube graduated in millimeters from 0 to 200, filling to the 0 mark	15 mm / hr	20 mm / hr

The tube is left standing undisturbed in a vertical position, and the fall of the level of RBCs in 1 hour is recorded in mm/hr. The volume of packed RBCs can then be determined using the same tube
• Katz index (KI) = [(mm in first hr) + (mm in second hr) / 2] / 2
ESR increases during :
• tissue necrosis
• anemias
• pregnancy
• obesity
• elevated levels of plasma proteins which decrease the zeta potential on erythrocytes by dielectric shielding and thus promote rouleau formation
• monoclonal gammopathy
• hypergammaglobulinemia due to inflammatory disease
• hyperfibrinogenemia
• active inflammatory disease
• zeta sedimentation ratio (ZSR) : a measurement comparable to the erythrocyte sedimentation rate, except that it is unaffected by anemia. The packed-cell volume (zetacrit) of a blood specimen is calculated by centrifuging the specimen in a Zetafuge, a specially designed instrument that produces controlled cycles of compaction and dispersion and allows rouleaux to form and sediment rapidly. The zetacrit divided into the true hematocrit gives the zeta sedimentation ratio.
• RBC protoporphyrin :
• 6-24 months : 79.79 +/- 14.3 mg/dL_RBC
• > 2 years : 58.6 +/- 13.6 mg/dL_RBC
Blood group or type : an allotype (or phenotype) of erythrocytes defined by one or more cell surface antigens that are under the control of allelic genes. There are > 250 different antigens on the surface of a RBC. Antigenic determinants irregularly incite allotypic and sometimes xenotypic immune responses. Human blood groups are identified by agglutination supported by specific human or animal antisera and by lectins extracted from certain plants. An abbreviated classification of human blood groups is given in the accompanying table. Any of certain other characteristics or traits of a cellular or fluid component of blood, considered as the expression (phenotype or allotype) of the actions and interactions of dominant genes; used in medicolegal and other studies of human inheritance. Such characteristics include the antigenic groupings of erythrocytes, leukocytes, platelets, and plasma proteins.
• high frequency blood group: a group containing over 99% of individuals, who have a type of erythrocyte antigens called public antigens.
• low frequency blood group : any small group that has erythrocytic antigens found in < 1% of the population (low frequency or private antigens).
Blood group system : antigenic determinants (symbols within parentheses are those of alternative nomenclatures. Antigenic determinants are systematized according to observed and assumed independent assortment of their responsible genes. Within many systems, alleles are responsible for differing combinations of antigenic determinants)
 

No.	Name	Symbol	Number of antigens	Gene symbol(s)	chromosome
001	ABO blood group : the major human blood group system, dependent on the presence or absence of A and B antigens, which are largely glycolipids on the cell membrane. The gene for A is responsible for synthesis of N-acetyl-a-D-galactosaminyl transferase, whereas that for B is responsible for a-D-galactosyl transferase. Either A or B is created when one of these hexasaccharides is positioned by a specific transferase in 1=>3 linkage to the b-D-galactose of an H-active oligosaccharide. Type O occurs when neither transferase is present or, very rarely (Bombay phenotype), when H antigen or substance (the precursor of the A and B blood group antigens. Normal type O individuals lack enzymes to convert H antigen to A or B antigens. Those individuals having the rare Bombay phenotype lack the ability to make H antigen and thus are phenotypically type O whether or not they possess A or B genes) does not exist. When both transferases are present, type AB results. Differences in degree of transferase activity are determined at the same locus: weak transferase gives rise to weak antigens (A2, A3Ax, B3Bx). Similar oligosaccharides, especially in bacterial cell walls, immunize persons lacking A or B so that their serum contains anti-A or anti-B activity. A and B antigens are on the mucopolysaccharides of secretors; persons with dominant genes have H-active mucoids. A [subgroups A1, A2, A3, Am, Ao, Ax, Aint, Aend, Afinn, Ae1, Abantu], B [subgroups B3, Bx, Be1]   phenotype genotypes frequency (%) antibodies present UK Congo India O O/O 43% 51% 31% anti-A, -B, -A,B A1 A1/A1, A1/O, A1/A2 35% 18% 26% anti-B A2 A2/A2, A2/O 10% 5% 3% sometimes anti-A1 B B/B, B/O 9% 21% 30% anti-A A1B A1/B 3% 2% 9% none A2B A2/B 1% 1% 1% sometimes anti-A1	ABO	4	ABO	9
002	MNSs blood group : a complex blood group system consisting principally of two pairs of antigens determined by closely linked genes (crossovers have been observed, but rarely). M and N, determined by allelic genes, depend on sialic (neuraminic) acid residues. S and s are also determined by allelic genes, and an amorphic gene is common in blacks when another antigen (U) is missing. The system also includes numerous low frequency antigens. Cla, Far, He, Hill, Hu, M, M1, MA, Mc, Me, Mg, Mk, Mr, Mv, Mz, Mia, Mta, Mur, N, NA, Na, N2, Nya, Ria, S, S2, SB, s, Sj, Sta, Sul, Tm, U, UB, Vr, Vw, Z	MNS	46	GYPA, GYPB, GYPE	4
003	P blood group : a blood group system originally consisting of only P (now P1) antigen, but later found to include P2 (Tja), a very high frequency antigen, and P3 (PK), a very low frequency antigen. P1 is most common in people of African descent (90%), less so in those of European descent (75%), and least in those of East Asian descent (30%) paragloboside : a biosynthetic precursor of the ABH and P1 blood group glycosphingolipids and of one class of gangliosides	P1	1	P1	22
004	Rh blood group : the most complex of all human blood groups because the genes differ by determining different numbers of antigens (Rhesus (Rh) factors or antigens : any of numerous antigens (agglutinogens) that may be present on the membrane of erythrocytes and that determine the Rh blood group system; the most common ones are called (in one system) Rh 1, Rh 3, Rh 4, Rh 5, and Rh 21) and do so with remarkably different quality; > 45 antigens have been described to date. People of African descent show the greatest degree of diversity and East Asians the least. The major antigen, Rh1 (Rh0, D, or Rh0D), is highly immunogenic and before the development of passive immunization prophylaxis it was responsible for serious hemolytic disease of the newborn (HDN). 2 other pairs of alternative antigens are inherited with or without Rh1; these are Rh21 (rhG or CG) and Rh4 (hr' or c), and Rh3 (rh' or E) and Rh5 (hr¢ or e). The most common groups of antigens are R-1,-3,-21 (in Caucasians), R1,-3,-21 (in blacks), R1,-3,21 (in East Asians and Caucasians), and R1,3,-21 (in East Asians and Caucasians). Another antigen Rh10 (hrv, V) is common in blacks. Rh1 (D, Rh0), Rh2 (C, rh´) Rh3 (E, rh´), Rh4 (c, hr´), Rh5 (e, hr´), Rh6 (ce, f, hr), Rh7 (Ce, Rhi), Rh8 (Cw, rhwl), Rh9 (Cx, rhx), Rh10 (V, ceS, hrv), Rh11 (Ew, rhw2), Rh12 (G, rhG), Rh13 (RhA), Rh14 (RhB), Rh15 (RhC), Rh16 (RhD), Rh17 (Hr0), Rh18 (Hr), Rh19 (HrS), Rh20 (VS, es), Rh21 (CG), Rh22 (CE), Rh23 (Dw), Rh24 (ET), Rh25 (LW), Rh26 (c-like), Rh27 (cE), Rh28 (hrH), Rh29 (RH), Rh30 (Dcor), Rh31 (hrB), Rh32, Rh33, Rh34 (HrB), Rh35, Rh36, Rh37, Rh38, Rh39, Rh40, Rh41, Rh42 (Ces)   phenotype frequency (%) genotypes D C c E e UK Nigeria Hong Kong + + - - + 18.5 0.7 56.0 DCe/Dce R1R1 DCe/dCe R1r' + - + + - 2.3 1.3 3.5 DcE/DcE R2R2 DcE/dcE R2r' + - + - + 2.1 58.9 0.2 Dce/dce R°r Dce/Dce R°R° + + - + - rare rare rare DCE/DCE RzRz DCE/dCE Rzry + + + - + 34.9 13.2 8.4 DCe/dce R1r DCe/Dce R1R Dce/dcE R2r + - + + + 11.8 18.3 2.1 DcE/dce R2r DcE/Dce R2R° Dce/dcE R°r" + + - + + 0.2 rare 1.1 DCe/DCE R1Rz DCE/dCe Rzr' DcE/dCE R1ry + + + + - 0.1 rare 0.3 DcE/DCE R2Rz DCE/dcE Rzr" DcE/dCE R2ry + + + + + 13.4 2.1 28.1 DCe/DcE R1R2 DCe/dcE R1r" DcE/dCe R2r' DCE/dce Rzr Dce/DCE R°Rz Dce/dCE R°ry - + - - + rare 0.1 rare dCe/dCe r'r' - - + + - rare rare rare dcE/dcE r"r" - - + - + 15.1 4.1 0.1 dce/dce rr - + - + - rare rare rare dCE/dCE ryry - + + - + 0.1 1.3 0.1 dCe/dce r'r - - + + + 0.1 rare rare dcE/dce r"r - + - + + rare rare rare dCe/dCE r'ry - + + + - rare rare rare dcE/dCE r"ry - + + + + rare rare rare dcE/dCe r"r' dCE/dce ryr	RH	50	RHD, RHCE	1
005	Lutheran blood group : a complex blood group system consisting of antigens Lua and Lub; it somewhat resembles the Kell group in having pairs of alternative antigens and amorphic genes, but is also subject to a dominant independently segregating repressor. Lua (Lu1), Lub (Lu2), Luab (Lu3), Lu4, Lu5, Lu6, Lu7, Lu8, Lu9, Lu10, Lu11, Lu12, Lu13, Lu14 (Swa)	LU	19	BCAM	19
006	Kell blood group : a blood group consisting of multiple erythrocytic antigens, especially 3 pairs of alternates, determined by complex genes at one locus, including an amorph; also regulated by the X chromosome, it is associated with sex-linked chronic granulomatous disease. One antigen, K6, is more frequent in people of African descent. K1 (K), K2 (k), K3 (Kpa), K4 (Kpb), K5 (Ku), K6 (Jsa), K7 (Jsb), K8 (kw), K9 (K1) K10 (U1a), K11 (Côté), K12 (Bøk), K13 (Sgro), K14 (San), K15 (Kx), K16 (K-like), K17 (Wka), K18, K19, Kpc McLeod phenotype : a rare blood phenotype with X-linked inheritance in which several antigens of the Kell blood group are weakly expressed; affected individuals sometimes have an anemic condition called McLeod syndrome	KEL	31	KEL	7
007	Lewis blood group : a blood group determined by plasma glycolipids that adhere to erythrocytic surfaces. It is based on dominant independent Le genes, but interacts with the H precursor oligosaccharides of A and B. Whereas le/le provides the “double negative” blood type Le(a-b-), Le without H gives rise to Lea, i.e., blood type Le(a+b-), and that with H gives rise to LebH, i.e., blood type Le(a-b+). Lea (Le1), Leb (Le2), Lec (Le5), Led, Lex (Lab, Le3), Mag (Le4)	LE	6	FUT3	19
008	Duffy blood group : a blood group consisting of the erythrocytic antigens Fya (Fy1), Fyb (Fy2), Fyab (Fy3), Fy4, Fy5, determined by allelic genes. Amorphic genes are common in individuals of African descent.   phenotype genotype frequency (%) Europeans Africans Fy(a+b-) Fya/Fya or Fya/Fy 20 10 Fy(a+b+) Fya/Fyb 48 3 Fy(a-b+) Fyb/Fyb or Fyb/Fy 32 20 Fy(a-b-) Fy/Fy 0 67 Nucleotide polymorphisms in the promoter region and in exon 2 of the 3 common alleles of the Duffy gene Allele GATA box sequence - 64 to -69 (promoter) codon 42 (exon 2) antigen Fya TTATCT GGT (Gly) Fya Fyb TTATCT GAT (Asp) Fyb Fy TTACCT GAT (Asp) red cells - none other tissues : probably Fyb	FY	6	DARC	1
009	Kidd blood group : a blood group consisting of Jka (Jk1), Jkb (Jk2), and Jkab (Jk3) antigens, determined by allelic genes; amorphic genes are most common in those of East Asian descent	JK	3	SLC14A1	18
010	Diego blood group : a blood group consisting of the erythrocytic antigens Dia and Dib, determined by allelic genes (SLC4A1 / erythrocyte membrane protein band 3 / CD233). Dia is most frequent in South American Indians, Japanese, and Chinese	DI	21	SLC4A1	17
011	Yt or Cartwright blood group : a blood group consisting of the erythrocytic antigens Yta and Ytb	YT	2	ACHE	7
012	Xg blood group : a blood group consisting of erythrocytic antigen Xga, which is determined by a gene on the long arm of the X chromosome	XG	2	XG, CD99	X/Y
013	Scianna blood group : a blood group consisting of erythrocytic antigens Sc1 (formerly Sm) and Sc2 (formerly Bua)	SC	7	ERMAP	1
014	Dombrock blood group [from the name of the propositus patient first observed in 1965] : a blood group consisting of the erythrocytic antigens Doa and Dob, most common in people of European descent	DO	6	ART4	12
015	Colton blood group : a blood group consisting of erythrocytic antigens Coa, Cob	CO	3	AQP1	7
016	Landsteiner-Wiener	LW	3	ICAM4	19
017	Chido/Rodgers : a blood group consisting of antigens Cha (Gursha) and Rga, antigenic determinants of fragments of the C4 component of complement.	CH/RG	9	C4A, C4B	6
018	H blood group : a blood group consisting of antigen H Bombay phenotype : a rare blood phenotype produced by the interaction of genes of the ABO blood group and a rare recessive gene at a different locus, resulting in a complete lack of H antigen; cells of individuals with this phenotype lack A, B, and H antigens, and their serum contains anti-A, anti-B, and anti-H antigen. Associated with leukocyte adhesion deficiency type 2	H	1	FUT1	19
019	Kx	XK	1	XK	X
020	Gerbich blood group : a blood group consisting of the erythrocytic antigens Ge 1, Ge 2, and Ge 3 (corresponding to glycophorin C and E); although rare in most parts of the world, it has been found often in Papua New Guinea	GE	8	GYPC	2
021	Cromer blood group : a blood group consisting of erythrocytic antigens Cra, Tca, Tcab, Dra, Esa, WESb, UMC, and IFC, which are located on the membrane protein called decay accelerating factor (DAF).	CROM	15	CD55	1
022	Knops blood group : a blood group consisting of antigens Kna, Knb, McCa, Sla, and Yka, which are located on complement receptor type 1.	KN	9	CR1	1
023	Indian	IN	4	CD44	11
024	Ok	OK	1	BSG	19
025	Raph	RAPH	1	CD151	11
026	John Milton Hagen	JMH	5	SEMA7A	15
027	I	I	1	GCNT2	6
028	Globoside	GLOB	1	B3GALT3	3
029	Gill	GIL	1	AQP3	9
030	RHAG	RHAG	3	RHAG	6

• Auberger blood group : a blood group consisting of the erythrocytic antigen Au^a, related to the Lutheran blood group
• Bg blood group : a blood group consisting of the erythrocytic HLA antigens Bg^a, Bg^b, Bg^c, DBG, Ho, Ho-like, Ot, and Sto
• Cost-Sterling blood group : Cs^a, Yk^a
• Ii blood group : a high frequency blood group involving receptors of most cold reactive hemagglutinins; it is expressed most strongly on cord blood cells : I, I^D, I^F, I^T, i
• Stoltzfus blood group : Sf^a
• Vel blood group : a blood group consisting of the erythrocytic antigens Vel 1 and Vel 2
• Wright blood group : a blood group consisting of the erythrocytic antigens Wr^a and Wr^b
Antigenic determinants that depend on gene interactions :
• ABO/I
• P/ABO
• IP1, IP2 (ITaj), ITP1, iP1
• Fy5,
• P/I
• Xor/Duffy
• ILe^bh
• Rh25 (LW)
• Lewis/I
• Rh/L^W
• A₁Le^b(Seidler)
• Lewis/ABO
• Ih, IA, IB, iH Luke
Selected antigenic determinants not thus far associated with a blood group system :
• Lan blood group : a blood group consisting of the erythrocytic antigen Lan.
• Sid blood group : a blood group consisting of those with extra amounts of the public erythrocytic antigen Sd^a, referred to as Sd(a++).
• 754
• An^a
• At^a
• Be^a
• Be^c
• Bi
• Big Charles
• Bpa
• Bra
• Bxa
• By
• Cad
• Car
• Chra
• Cip
• Coates
• Craig
• Dahl
• Donaviesky
• Dp
• Driver
• Duch
• E1
• En^a
• Evans
• Evelyn
• Fin
• Fuerhart
• Fuj
• Gf^a
• Gilbraith
• Gn^a
• Go^b
• Good
• Green
• Gy^a
• Hands
• Hen
• Heibel
• Hill
• Ht^a
• Hy
• Je^a
• Jn^a
• Jo^a
• Jo^b
• Jr
• Kam
• Kelly
• Ken
• Knops (Kn^a)
• Kosis
• Lev
• Lw^a
• McCall
• McCoy (McC^a)
• Man
• Mar
• Mo^a
• MZ443
• Nij
• Ola
• Orr
• Pea
• Pt^a
• Rd^a
• Reid
• Savior
• Sch
• Simon
• Skjelbred
• Ters
• Th^a
• To^a
• Todd
• Tr^a
• Ven
• Vennera
• Wb
• Weeks
• Wil
• Winbourne
• Wu
• Yh^a
• York (Yk^a)
• Za
Bibliography : Blood Groups and Red Cell Antigens by Laura Dean; Bethesda (MD): National Library of Medicine (US), NCBI; 2005 [free at NCBI BookShelf !]
Web resources : Blood Group Antigen Gene Mutation (BGMUT) Database
Erythrocyte survival time :
• ⁵¹Cr release assays (gold standard)
• erythrocyte creatine is thought to be a sensitive parameter of erythrocyte age^{ref1, ref2, ref3, ref4}. In hemolytic patients, it has been demonstrated that erythrocyte creatine was closely correlated with the erythrocyte survival time, which was evaluated by the standard procedure involving ⁵¹Cr^ref. The young erythrocytes have higher creatine values than do the old cells^{ref1, ref2}
Erythrocatheresis occurs mainly by macrophages in Schweigger-Seidel sheaths (red pulp of spleen) : as senescent erythrocytes down-regulate CD47 expression, PTPNS1 / SIRPa (an-ITIM containing inhibitory receptor) can no longer prevent phagocytosis.

‡
• ghost cell / erythroclast / shadow cell : a degenerating or fragmented erythrocyte with no hemoglobin
+ M-CSF
• BFU-Meg => megakaryocytopoiesis. In bone marrow precursors are located in a position intermediate between that of WBC precursors and that of RBC precursors.
‡
+ M-CSF / CSF-1, EPO, IL-3, TPO, thrombopoiesis stimulating factor :
• CFU-Meg (PPo⁺)

‡
+ EPO, IL-3, TPO : TPO supports progenitor cell expansion, whereas CXCL12, FGF-4 enhance VCAM-1 and VLA-4-mediated localization of CXCR4⁺ megakaryocyte  progenitors with the bone marrow endothelial cells (BMECs) allows the progenitors to relocate to a microenvironment that is permissive and instructive for megakaryocyte maturation and thrombopoiesis^ref
• promegakaryoblast

‡
+ EPO, TPO, LIF, OsM, IL-1b, IL-3, IL-4, IL-6, IL-11, thrombopoiesis stimulating factor, megakaryocyte maturation factor (inhibited by IFN-a, IFN-g, TGF-b, CXCL4 / PF4 and b-thromboglobulin). GABP-a, an Ets transcription factor, is required for the early maturation of megakaryocytes and controls the expression of multiple megakaryocyte-specific genes aIIb and cMpl^ref.
• megakaryoblast (CXCL4 / PF4⁺, CD42b / glycocalicin / gpIb_a⁺42c / gpIb_b⁺, vWF⁺, fibrinogen ABg⁺, factor V⁺, thrombospondin⁺, AcP⁺, 4n)


‡
+ IL-6, IL-7, TPO : endomitosis followed by nuclear fusion => autopolyploidy.
• promegakaryocyte or immature megakaryocyte (from 8n up to 128n).


It hasa-granules, which contain :
• CXCL4 / PF4 / antiheparin factor
• b-thromboglobulin => connective tissue-activating peptide III (CTAP-III) (normal serum levels : 1.6-4.8 µM^ref) => CXCL7 / LDGF-PBP / NAP-2 / CTAP-II
• fibronectin
• vitronectin / protein S
• thrombospondin
• fibrinogen ABg
• vWF
• factor V
• factor VIII
• a subunit of factor XIII
• a₁-antitrypsin / a₁-antiplasmin
• PA-I
• PDGF
• PD-ECGF
• CXCL4 / PF4
• TGF
• HGF
• EGF
• PrP^C (platelet activation led to the transient expression of PrPC on the platelet surface and its subsequent release on both microvesicles and exosomes)^ref
‡
• reserve megakaryocyte

‡
down-regulation of survivin => continue to progress through the cell cycle but skip late stages of mitosis to become polyploid cells^ref. Fli-1, an Ets transcription factor, is required for the late maturation of megakaryocytes and controls the expression of multiple megakaryocyte-specific genes^ref.
• mature megakaryocyte (CD42a / p17^gpIX+42b / glycocalicin / gpIb_a⁺42c / gpIb_b(containing HPA-2a / Ko^b and HPA-2b / Ko^a Ags)⁺42d / p82^gpV+)


In 1906, James Wright (Wright JH. The origin and nature of the blood plates. Boston Med Surg J. 1906;154: 643-645) published a morphology study in which he argued that circulating plates (then called platelets) are derived from megakaryocytes, and that megakaryocytes release platelets from elongated, cytoplasmic projections that extend into the marrow sinusoids. Following a series of mitotic cell divisions, megakaryocyte lineage cells enter an endomitotic cycle that generates large, polyploidy megakaryocytes. Cytoplasmic maturation at the end of the endomitotic phase includes the development of the demarcation membrane system (DMS). The DMS, first described by Yamada in 1957^ref, is an extensive membrane network located throughout the cytoplasm of the mature megakaryocyte, except for a thin, uninvolved cortical zone. Staining studies have shown that the DMS is contiguous with the extracellular space, making it effectively an extensive invagination of surface membrane, but its function remains unclear. One early popular theory, which is reflected in its name, is that the DMS "marks" preformed "platelet territories" within the megakaryocyte cytoplasm, which in turn led to the cytoplasmic fragmentation hypothesis for platelet formation. However, this is incompatible with proplatelet formation (thrombocytopoiesis) as the mechanism of platelet biogenesis. Using novel knock-in mice in which the fluorescent protein EYFP is introduced into the CD41 (integrin IIb) locus, the DMS serves as an extensive membrane reservoir to support the explosive proplatelet formation that marks the final hours of the mature megakaryocyte^ref. Key to their studies is a C-terminal myristoylation site that incorporates the EYFP reporter into cellular membranes. The EYFP signal localizes to the outer cell membrane of early megakaryocyte lineage cells, but it becomes diffusely localized throughout the cytoplasm in mature megakaryocytes in a pattern that mirrors the DMS. The EYFP-expressing internal membranes were found to be contiguous with the full outline of emerging proplatelets, and platelets circulating in the EYFP mice have surface EYFP fluorescence, data compatible with the DMS providing an extensive membrane reservoir for proplatelet formation. Using fluorescently tagged plextrin homology domain from PLC1 as a probe, the phospholipid PI-4,5-P₂, which typically resides in the plasma membrane of cells, localizes to the DMS in mature megakaryocytes. siRNAs suggest that the accumulation of PI-4,5-P₂ on the DMS membranes, along with DMS development and the associated increase in cell size, may all be facilitated by the lipid kinase PIP4K. PI-4,5-P₂ signaling from the DMS may trigger actin polymerization via the WASp/WAVE pathway. Reports over the past 5 years have significantly advanced our understanding of the structural and mechanical aspects of proplatelet formation^{ref1, ref2}. From each proplatelet arises more than one ...
‡ The generation of platelets from megakaryoctes is regulated ...
• in the steady state by a variety of cytokines and transcription factors, including thrombopoietin (TPO), GATA-1 and NFE2 => the kinase adaptor protein LIMS1/PINCH1^ref
• in the setting of stress thrombopoiesis, a pivotal event in the context of cytotoxic chemotherapy, by the transcription factor Scl, which acts upstream of NFE2^ref
• platelet / thromboplastin / Deetjen's body

They don't contain DNA (instead in lower Vertebrates they retain nucleus and are named thrombocytes) but just cytoplasmic enzymes for all metabolic cycles, mitochondria, peroxisomes and glycogen granules.
Bone marrow produces 100,000,000,000 platelets / die, as estimated with ⁷⁵Se-Met and ¹⁴C-5-HT incorporation tests. Normal valeus :
• platelet count (PLT) (either a direct platelet count with a hemacytometer and a microscope or an indirect platelet count in which the ratio of platelets to erythrocytes on a blood smear is determined and the number of platelets is computed from the erythrocyte count) = 1.5 ^. 10⁹ / weight Kg ; 172,000÷500,000 / mL blood ; 0.4 % total blood cells, although they are rather just cell fragments !) : 40,000 / mL are replaced each day
• t_1/2 : 2 days
• average life estimated with ⁵¹Cr or ¹¹¹In release tests = 8÷10 days
• plateletcrit (PCT) = 0.115÷0.32 %
• mean platelet volume (MPV) = PCT / PLT = 9.1÷12.3 fL
• platelet distribution width (PDW) = 10÷16 fL
Apart from a-granules, they also contain :
• d-granules / bull's eye or platelet dense body or granule : an electron-dense granule occurring in blood platelets that stores and secretes  ADP, ATP, GDP, GTP, PP_i, P_i, P, Ca²⁺, Mg²⁺, 5-HT, E and H)
• l-granules / lysosomes (containing AcP, arylsulfatase, cathepsin D, b-glucuronidase and b-galactosidase)
Platelet factors (PF) : factors important in hemostasis which are contained in or attached to the platelets; they act together with coagulation factors.
• platelet factor 1 (PF1) : adsorbed factor V from the plasma.
• platelet factor 2 (PF2) : an accelerator of the thrombin-fibrinogen reaction, attached to platelets.
• platelet factor 3 (PF3) : a lipoprotein, extracted from platelets, which contributes to the interaction of activated plasma coagulation factors IX and VIII to produce activated factor X as well as of activated factors X and V to cleave and activate prothrombin.
• platelet factor 4 (PF4) / CXCL4 : an intracellular protein component of blood platelets, capable of neutralizing the antithrombic activity of heparin in the fibrinogen-fibrin reaction and the inhibitory effect of heparin in the thromboplastin generation test. Normal serum level : 0.4-1.9 µM^ref.
Main membrane proteins are : CD14^-15^-23⁺31 / PECAM-1 / b₁ integrin / p130^gpIIa
+36 / thrombospondin receptor / p95^{gpIV / gpIIIb+}41 / a_IIb integrin / p136^gpIIb (containing HPA-3a / Bak^a / Lek^a and HPA-3b / Bak^b / Lek^b Ags)⁺42a / p17^gpIX+42b / glycocalicin / gpIb_a⁺42c / gpIb_b (containing HPA-2a / Ko^b and HPA-2b / Ko^a Ags)⁺42d / p82^gpV+43^lo46⁺49 / a₂ integrin / p153^gpIa (containing HPA-5a / Br^b and HPA-5b / Br^a / Hc / Zav Ags)⁺61 / b₃ integrin / p95^gpIIIa(containing HPA-1a / PI^A1 / Zw^a, HPA-1b / PI^A2 / Zw^b, HPA4a / Pen^a / Yuk^b and HPA-4b / Pen^b/ Yuk^a Ags)⁺69⁺MHC class I⁺, P2Y₁, P2Y₁₂, P2_T, TP, PAR-3, PAR-4, 5-HT_2A, CD88 / C5aR, AB0, Le, I and P blood group Ags, Gov^a and Gov^bAgs, p148^gpIc.
TLR2 and TLR4 are expressed at low levels on platelets, but TLR agonists LPS and Pam3CSK4 have no direct effect on platelet activation and that platelet TLRs may be a remnant from megakaryocytes^ref.
Receptors for collagen and adenosine diphosphate (ADP) undergo synergistic signaling to integrin a_IIbb₃ for platelet aggregation^ref. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation^ref

Platelet aggregation, which contributes to arrest bleeding but also to thrombovascular disorders, is thought to initiate after signaling-induced activation. This paradigm does not apply under blood flow conditions comparable to those existing in stenotic coronary arteries. Platelets interacting with immobilized vWF aggregate independently of activation when soluble vWF is present and the shear rate exceeds 10,000/s (shear stress 400 dyn/cm²). Above this threshold, active A1 domains become exposed in soluble VWF multimers and can bind to glycoprotein Ib promoting additional platelet recruitment. Aggregates thus formed are unstable until the shear rate approaches 20,000/s (shear stress 800 dyn/cm²). Above this threshold, adherent platelets at the interface of surface-immobilized and membrane-bound vWF are stretched into elongated structures and become the core of aggregates that can persist on the surface for minutes. When isolated dimeric A1 domain is used instead of native vWF multimers, activation-independent platelet aggregation occurs without requiring shear stress above a threshold level, but these aggregates never become firmly attached to the surface and progressively disaggregate as shear rate exceeds 6,000/s. Platelet and vWF modulation by hydrodynamic force is a mechanism for activation-independent aggregation that may support thrombotic arterial occlusion^ref
Experimental models : Pf4-Cre transgenic mice allow generating lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo^ref
Human platelet antigen (HPA) system :

HPA system	antigen	alternative names	phenotype frequency in caucasians (%)	glycoprotein	SNP	dbSNP rs number	amino acid change
1	1a	Zwa, PlA1	97.9	GPIIIa	T196	rs5918	Leucine33
	1b	Zwb, PlA2	28.8		C196		Proline33
2	2a	Kob	>99,9	GPIba	C524	rs6065	Threonine145
	2b	Koa, Siba	13.2		T524		Methionine145
3	3a	Baka Leka	80.95	GPIIb	T2622	rs5911	Isoleucine843
	3b	Bakb	69.8		G2622		Serine843
4	4a	Yukb, Pena	>99.9	GPIIIa	G526	rs5917	Arginine143
	4b	Yuka, Penb	<0.1		A526		Glutamine 143
5	5a	Brb, Zavb	99.0	GPIa	G1648	rs10471371	Glutaminc acid505
	5b	Bra, Zava, Hca	19.7		A1648		Lysine505
6				GPIIIa	G1564	rs13306487	Arginine489
	6bw	Caa, Tua	0.7		A1564		Glutamine489
7				GPIIIa	C1267		Proline407
	7bw	Moa	0.2		G1267		Alanine407
8				GPIIIa	T2004		Arginine636
	8bw	Sra	<0.01		C2004		Cysteine636
9				GPIIb	G2603		Valine837
	9bw	Maxa	0.6		A2603		Methionine837
10				GPIIIa	G281		Arginine62
	10bw	Laa	< 1.6		A281		Glutamine62
11				GPIIIa	G1996		Arginine633
	11bw	Groa	< 0.25		A1996		Histidine633
12				GPIbb	G141		Glycine15
	12bw	Iya	0.4		A141		Glutamin acid15
13				GPIa	C2531		Threonine79
	13bw	Sita	0.25		T2531		Methionine79
14				GPIIIa
	14bw	Oea	< 0.17		DAAG1929-1931		DLysine611
15	15a	Govb	74	CD109	C2108	rs10455097	Serine703
	15b	Gova	81		A2108		Tyrosine703
16				GPIIIa	C517		Threonine140
	16bw	Duva	< 1		T517		Isoleucine140
17				GPIIIa	C622		Threonine195
	17bw	Vaa	< 0.4		T622		Methionine195

+ ? :
• precursor of myeloid, B and T cells (p-MTB) or common myelo-lymphoid progenitor (CMLP)

(CD16a / FcgRIIIA⁺32 / FcgRII⁺)
‡
+ ? :
• precursor of myeloid and B cells (p-MB)

(please note all stages in B cell lineage (until mature B-cell stage) are potent APCs and retain the ability to show dendritic morphology, up to convertion into macrophages). The decision to become a B cell or macrophage depends on which transcription factor between C/EBP (C/EBP-a and C/EBP-b : myeloid commitment) and PAX5 / BSAP (B-cell commitment) becomes dominant^ref.

or

+ ? :

• precursor of myeloid and T cells (p-MT)

(please note early thymocytes are able to generate dendritic cells)
• lymphopoiesis => B and T cells(they appear as WBCs, too). Normal blood concentration : 0.16÷0.32 ^. 10⁹ lymphocytes / weight Kg ; 0.88÷4.52 ^. 10³ lymphocytes / mL blood ; 0.32÷0.64 % total blood cells ; 20÷40 % total WBCs.
• small lymphocytes are the most common, ranging in size from 6 to 10 µm. The nucleus is usually round or slightly oval, occasionally showing a small indentation due to the adjacent centrosome. Except in the smallest cells, the nucleus is about 7 µm in diameter, a size that has been convenient for estimating the size of the surrounding erythrocytes. Nuclear chromatin stains a dark reddish-purple to blue with large dark patches of condensed chromatin. The nuclear cytoplasm ratio is 5:1 to 3:1, and the cytoplasm is often seen only as a peripheral ring around part of the nucleus


• myelopoiesis => leukocytes or white blood cells (WBC)

‡
+ GM-CSF
• colony-forming unit–granulocyte-macrophage (CFU-GM) / colony-forming unit–culture (CFU-C) : a precursor cell in the granulocytic series that can grow into a myeloblast in the presence of appropriate stimulators in vitro (CD13⁺33⁺34⁺, MHC II⁺). Within 10 days a myeloblast becomes a granulocyte.

‡
+ G-CSF, IL-3, IL-6, GFI1, PU.1 / SPI1, C/EBPa, C/EBPe :
• CFU-G. The myeloid commitment of hematopoietic progenitors is characterized by the progressive loss of CD34 expression accompanied by the acquisition of expression at high levels of CD33, a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. CD33 expression continues along the myelomonocytic pathway of differentiation. Although this expression is maintained on monocytes and its 2 terminal stages of differentiation (ie, tissue macrophages and myeloid DCs), a down-regulation is observed on granulocytes, which, however, continue to express CD33 but only at low levels^{ref1, ref2}

‡
• myeloblast (CD33⁺34⁺, MHC II⁺) : a myeloblast is the earliest recognizable cell of the neutrophilic series. It is usually 15-20 µm in diameter. The nucleus is round or slightly oval and occupies about 4/5 of the cell. The nucleus is composed of very fine nonaggregated chromatin that stains light blue to reddish-purple with Wright's stain. 2-5 distinct nucleoli are usually present. The nucleus is often bordered at one side by a distinct perinuclear zone. The cytoplasm is usually moderately blue in color, smooth, and nongranular. It occupies one-fifth of the cell. It may be difficult to distinguish myeloblasts from other blasts in the peripheral blood unless one uses special stains or infers their identity from the presence of other immature cells of the same line. A myeloblast can be distinguished from a promyelocyte by its lack of cytoplasmic granulation. It develops into a granulocyte within 10 days


‡
• neutrophil promyelocyte (CD11b⁺13⁺15⁺33⁺34⁺73 / ecto-5'-nucleotidase⁺, MHC II⁺) :


• primary, azurophilic or aspecific granules (~ lysosomes) contain :
• 3 serine proteases^ref :
• elastase 2 (ELA2) / human leukocytary elastase (HLE) / medullasin / neutrophil elastase (NE)
• cathepsin G (CG)
• proteinase 3
• myeloperoxidase (MPO : used for histochemical identification !)
• b-galactosidase
• acidic hydrolases
• b-glucuronidase
• acid phosphatase (AcP)
• ...
• arylsulfatase B
• cationic proteins
• defensins
• azurocidin
• BPI / CAP57
• lysozyme
CD63, CD68, and stomatin (STOM) are the only membrane proteins identified so far
‡
• myelocyte (CD11b⁺13⁺15⁺33⁺34^-, MHC II^-) : disappearance of nucleoli



• primary / azurophilic / aspecific granules (~ lysosomes)
• secondary / specific granules :
• lactoferrin / lactotransferrin
• group II phospholipase A₂
• TC-I
• TC-II
• lysozyme
• MMP-2 / gelatinase A / type IV collagenase
• MMP-9 / gelatinase B
• alkaline phosphatase (AlkP)
• phagocytins / cathelicidins
• cytochrome b
• b₂-microglobulin
• lipocalin 2 / human neutrophil lipocalin (HNL) / NGAL
• haptoglobin : neutrophils contain a large amount of highly glycosylated Hp (b-chain 45-65 kDA) that is synthesized in neutrophil precursors and stored in specific granules, as well as a small amount of Hp (b-chain 39 kDA) endocytosed from plasma and stored in secretory vesicles^ref
&darr;
• metamyelocyte / juvenile cell (CD11b⁺13⁺15⁺33^-34^-, MHC II^-) :
• primary / azurophilic / aspecific granules (~ lysosomes)
• secondary / specific granules
• tertiary granules / C particles
• cathepsin G
• MMP-2 / gelatinase A
• MMP-9 / gelatinase B


They have a cell diameter from 10 to 18 µm, and the nucleus to cytoplasm ratio is 1:1. Indentation of the nucleus begins at this stage, forming an outline that varies from slightly kidney shaped, to that of a broad V shape.
‡
• band cell, band form or neutrophil / rod neutrophil / stab cell or neutrophil : a late metamyelocyte in which the nucleus is in the form of a curved or coiled band, not having acquired the typical multilobar shape of the mature PMN neutrophil. Promyelocytic NB4 leukemia cells undergo differentiation to granulocytes following retinoic acid treatment. Tissue transglutaminase (TG2), a protein cross-linking enzyme, was induced, then partially translocated into the nucleus and became strongly associated with the chromatin during the differentiation process. The transglutaminase-catalysed cross-link content of both the cytosolic and the nuclear protein fractions increased while NB4 cells underwent cellular maturation. Inhibition of cross-linking activity of TG2 by monodansylcadaverin in these cells led to diminished nitroblue tetrazolium (NBT) positivity, production of less superoxide anion and decreased expression of gp91^phox, the membrane-associated subunit of NADPH oxidase. Neutrophils isolated from TG2^-/- mice showed diminished NBT reduction capacity, reduced superoxide anion formation and down-regulation of the gp91phox subunit of NADPH oxidase, as compared to wild type cells. It was also observed that TG2^-/- mice exhibited increased neutrophil phagocytic activity, but had attenuated neutrophil chemotaxis and impaired neutrophil extravasation with higher neutrophil counts in their circulation during yeast-extract induced peritonitis. These results clearly suggest that TG2 may modulate the expression of genes related to neutrophil functions and is involved in several intra- and extracellular functions of extravasating neutrophil^ref.


• neutrophilic polymorphonuclear (PMN) granulocyte / neutrophil (CD5^-11a⁺11b⁺13⁺14^lo15⁺16b / FcgRIIIB⁺19^-32 / FcgRIIA⁺33^-CD35 / CR1⁺34^-43^hi46⁺49d⁺68⁺69⁺88 / C5aR⁺89⁺153 / 30L⁺ , MHC II^-, A₁, A_2A, TLR1, TLR2, TLR4, TLR6, TLR8 greater than TLR5, TLR9, and TLR10 greater than TLR7^ref) : they are usually 9 to 16 µm in diameter. The nuclear lobes, normally numbering from 2 to 5, may be spread out so that the connecting filaments are clearly visible, or the lobes may overlap or twist. The chromatin pattern is coarse and clumped. The cytoplasm is abundant with a few nonspecific granules and a full complement of rose-violet specific granules :
• primary / azurophilic / aspecific granules (~ lysosomes)
• secondary / specific granules
• tertiary granules / C particles
• secretory vesicles (AlkP, plasma proteins, ..)
• myeloid-related proteins (MRPs)
• S100A8
• S100A9
• S100A12
Ca²⁺-binding proteins that belong to the S100 protein family : S100A8 and S100A9 associate noncovalently to form homodimers and the heterodimr S100A8/A9.
Bone marrow produces 8 ^. 10⁷ cells / _min ~ 10¹¹ cells /_die = 6 ^. 10⁹ cells / _{kg / die}.
Average life : 6-12 hrs in blood (death by apoptosis), up to 4 hrs in tissues.
Normal blood concentration : 0.4 ^. 10⁹ neutrophils / weight Kg ; 2.2÷7.91 ^. 10³ neutrophils / mL ; 0.8÷1.12 % total blood cells ; 40÷75 % total WBCs.
Tissue reservoirs contain 6.9 ^. 10⁹ cells / _kg.
Unique Rac2 localization and functions in neutrophils are regulated by 2 separate C-terminal motifs, the hypervariable domain and aspartic acid 150 and Rac1 localization depends on Rac2 activity^ref.
Segmented neutrophil (segs) : a mature neutrophil in which the nucleus is divided into definite lobes joined by a filamentous connection, as distinguished from a band cell.

During acute infections releasing from storages (marginal neutrophil adhesed on endothelial walls in spleen) allows reaching 10x [ ]. Activation of RhoA kinase 1 (ROCK1) promotes leukocyte de-adhesion by inhibiting cytoskeletal-dependent spreading, so decreasing binding avidity. Click here for neutrophil migration into tissues.
During oxidative burst, R.O.S. can lethally damage the granulocytes themselves, which undergo steatosis and create pus. They produce IL-4. They contain 80÷90 % of specific granules and 10÷20 % of primary granules inherited during mitosis. 3% of PMNs in females (and males with Klinefelter syndrome) contain a nuclear appendix called Davidson's body, corresponding to Barr's body (inactive X chromosome of the females :
• drumstick shaped nuclear appendage. ± 1,5 µm in diameter and attached to the nucleus by a filament


• sessile nodule


With aging nucleus undergoes segmentation : Arneth neutrophil lobe count : a method of determining what % of neutrophils in a population have each number of nuclear lobes or segments between 1 and 5; normally over 75% should have 2-3 lobes. An increase in the percentages with fewer lobes, called a shift to the left, is seen in bacterial infections, whereas an increased number with hypersegmentation of the nuclei, called a shift to the right, is seen in cobalamin and folate deficiency
• Arneth scheme : plotting of segments number frequency
• Arneth index = percentages with 1 or 2 lobes + half the percentage with 3 lobes = 60%
• average lobe index (ALI) of the neutrophils = total number of nuclear lobes in 100 neutrophils / 100 = 2.5 - 3.1 (mean : 2.8).
Other parameters :
• mean peroxidase index / myeloperoxidase index (MPXI) =
TCRab is expressed on the surface of a 5–8% subpopulation of human neutrophils and in native and differentiating human HL-60 APL cells. TCR expression in HL-60 cells is supported by two studies in the murine promyelocytic cell line MPRO that demonstrate expression of the TCRb and TCRg mRNAs and the Rag1 protein during MPRO differentiation into mature neutrophils^{ref1, ref2}.  TCR engagement through the CD3/CD28 pathway enhances bcl-x_L expression, protects neutrophils from apoptosis, and leads to increased IL-8 / CXCL8 / NCF secretion. These results in humans are consistent with the finding that neutrophils from several mouse strains also express TCR V repertoires, suggesting that this may be a general feature of mammalian neutrophils. In unstimulated neutrophils, a band was detected that was slightly larger than 47 kDa, consistent with the presence of a previously reported differentially glycosylated TCR variant^ref. Monoclonal antibodies to CD3 and CD28^ref are commonly used to mimic activation of the TCR. Activation with CD3 and, to a lesser degree, CD28 antibodies triggered induction of TCR. These results are in line with the finding that human neutrophils express CD3z and CD28^ref. Both cell types also express the CD3z chain^ref, z-chain-associated protein kinase 70 (ZAP70)^ref, and linker for activation of T cells (LAT)^ref. ATRA-mediated differentiation induced up-regulation of CD3 and ZAP70 mRNA levels in HL-60 cells but had no effect on expression of LAT and TCR constant chains. Moreover, CD3- or CD28-activating antibodies resulted in increased CD3z but not ZAP70 expression. Representative analysis of the Va14 and Vb14 CDR3 spectratypes revealed Gaussian and skewed (Vb14 Neutrophils 1) CDR3 length distribution profiles indicative of complex Vab repertoires as they are observed in T cells^ref, and they change over time. Neutrophils showed positive staining for CD16 (and the myeloid lineage markers CD15 and CD33) but not for T cell markers (CD3, CD4, and CD8). RAG1 and RAG2 are constitutively expressed in HL-60 cells and circulating neutrophils, while peripheral blood T cells only express RAG2. TCR CDR3 spectratyping confirmed the presence of complex Va5 and Vb16 repertoires in the neutrophil fraction of normal 129/SvJ mice. Neutrophils from T cell-deficient CD1 nude mice also expressed TCR V repertoires, whereas no evidence for TCR V repertoire expression was found in neutrophils from recombination-defective C.B17 SCID mice. G-CSF suppressed mRNA expression of all neutrophil TCR constant chains and components of the TCR signaling complex (CD4, CD3z, ZAP70, and LAT) during the first 48 h after injection. G-CSF induced up-regulation of RAG1 for a period of 48 h, which was paralleled by a moderate down-regulation of generally high RAG2 levels. The additional lower-molecular-mass RAG1 bands have been previously observed^ref. Consistent evidence for TCR expression in neutrophils from T cell-deficient individuals and mouse strains lacking T lymphocytes dismisses the possibility that the presence of the TCR in neutrophils is the mere result of "passive receptor expression," e.g., because of phagocytosis of TCR-bearing lymphocytes. This finding is also supported by routine detection of RAG1 expression in human neutrophils, which cannot be attributed to ingestion of T cell material because RAG1 is absent from postthymic T cells. Neutrophils have a half-life of only 6–10 h in the circulation and a rapid turnover rate (Savill, J & Haslett, C. (1994) in Immunopharmacology of Neutrophils eds. Hellewell, PG & Williams, TJ. (Academic, San Diego,) pp. 295–314). Given these dynamic features, it is conceivable that the TCR⁺ neutrophil may represent a first line system of antigen-specific defense. Such a rapid and highly flexible immunological intervention system would make sense because it may complement the conventional T cell-based cellular host defense with its relatively slow temporal dynamics^ref. The observed induction of IL-8 secretion after engagement of the neutrophil TCR raises the possibility that activation of TCR⁺ neutrophils by specific antigens may potently and rapidly boost the recruitment of additional neutrophils to sites of inflammation where these antigens are present. Such a mechanism may efficiently facilitate the response to antigens during early phases of host defense^ref.
In 1998, the Granulocyte Antigen Working Party of the ISBT introduced a new nomenclature for human neutrophil antigens (HNA), which is based on the antigens' glycoprotein location. In the HNA nomenclature the immunogenic (glyco-) proteins are indicated by arabic numbers followed by a letter of the alphabet which identify the (glyco-) proteins' polymorphisms, i.e. the specific antigens. Currently, 7 HNA antigens are assigned to 5 systems.
• The HNA-1a, HNA-lb and HNA-1c antigens, the former NA1, NA2, and SH antigens, have been identified as polymorphic forms of the neutrophil FcgRIIIb (CD16b) encoded by 3 alleles.
• HNA-2a (former NB1) bearing glycoprotein as a novel member of the Ly-6/uPAR superfamily which has been clustered meanwhile as CD177.
• HNA-3a antigen, the former 5b, is located on a 70-95 kDa glycoprotein. However, its molecular basis is still unknown.
• HNA-4a and HNA-5a antigens, the former MART and OND, were found to be caused by single nucleotide mutations in the a_M (CD11b) and a_L (CD11a) subunits of the leucocyte adhesion molecules (b₂ integrins).
The glycoproteins CD11b, CD16b, and CD177 have been found to be also frequent targets of autoantibodies - approximately 30% of neutrophil autoantibodies are directed against CD16b^ref.
Human neutrophil antigen (HNA) system :

HNA system	antigen	original acronym for antigen	phenotype frequency in Caucasians (%)	glycoprotein	nucleotide change	amino acid change
1	1a	NA1	46	FcgRIIIb	G108	Arginine36
					C114	none
					A197	Asparagine65
					G247	Aspartic acid82
					G319	Valine106
	1b	NA2	88	FcgRIIIb	C108	Serine36
					T114	none
					G197	Serine65
					A247	Asparagine82
					A319	Isoleucine106
	1c	SH+	5	FcgRIIIb	A266	Aspartic acid78
		SH-			C266	Alanine78
2	2a	NB1	97	CD177	not known	not known
-		NB2	32	not known	not known	not known
-	ND	ND1	98.5	not known	not known	not known
-	NE	NE1	23	not known	not known	not known
-	LAN	LANa	>99	FcgRIIIb	not known	not known
-	SAR	SARa	>99	FcgRIIIb	not known	not known
-	Five	5a	-	not known	not known	not known
3a	Five	5b	-	70-95 kDa	not known	not known
4a	Mart	Marta(+)	99.1	CD11b	G302	Arginine61
		Marta(-)		CD11b	A302	Histidine61
5a	Ond	Onda(+)	>99	CD11a	G2466	Arginine766
		Onda(-)		CD11a	C2466	Threonine766

+ M-CSF, GM-CSF, IL-3, IL-4, IL-6, IL-13, ICSBP / IRF-8, C/EBPa^ref (monopoiesis) :
• CFU-M

‡
+ M-CSF :
• monoblast


‡
+ IRF2 is required for the development of splenic and epidermal CD4⁺8a^-11b⁺11c⁺ DCs^ref
• promonocyte (CD13⁺14⁺15⁺33⁺, MHC II⁺). After 4 dd. from CFU-M formation, promonocytes are released into bloodstream.


‡
• monocyte (CD11b^lo11c^hi13⁺14⁺15⁺33⁺CD35 / CR1⁺43^hi68⁺83^-86 / B7-2^hi88 / C5aR⁺91 / LRP / a₂-macroglobulin R⁺153 / 30L⁺NKG2D^- , MHC II⁺) (a-naphtyl butyrate esterase and chloro-acetate esterase (CAE) are used for histochemical identification !)
• classical monocytes (CD14⁺⁺16b/FcgRIIIB^-MHC II⁺CCR2^-) are recruited to non-inflamed tissues and these cells might be the precursors of tissue-resident macrophages and DCs)
• proinflammatory monocytes (CD14⁺16b / FcgRIIIB⁺MHC II⁺⁺CCR2⁺) are short-lived cells that are recruited to inflamed tissues

monocytic granule : one of the fine red azurophilic granules of a monocyte.
Both subsets have the capacity to develop into DCs.
Phagocytosis of platelets down-regulates monocyte apoptosis. After some days in blood (t_1/2 = 1-3 days), they migrate into tissues and become:
‡ + RelB. Upon M-CSF exposure, caspase-8 associates with the adaptor protein FADD, the serine/threonine kinase RIP1 and the long isoform of FLICE-inhibitory protein FLIP. Overexpression of FADD accelerates the differentiation process that does not involve any death receptor. Active caspase-8 cleaves RIP1, which prevents sustained NF-kB activation, and activates downstream caspases. Altogether, these data identify a role for caspase-8 in monocytes undergoing macrophagic differentiation, i.e. the enzyme activated in an atypical complex down-regulates NF-kB activity through RIP1 cleavage^ref.
Monocytes, like all leukocytes, undergo a series of sequential steps during extravasation from blood into tissues:
• tethering
• rolling
• adhesion
• locomotion : blocking CD11a-CD18 and CD11b-CD18 on human monocytes or adhesion molecules ICAM-1 and ICAM-2 on endothelial cells prevented the monocytes from reaching junctions. The blocked monocytes spun in circles as if they were unable to direct their movement despite being able to adhere and polarize normally^ref
• diapedesis
• in tissues as tissue macrophage (Mf) / endothelial leukocyte / rhagiocrine cell / histiocyte / quiescent bone marrow-derived dendritic cell (BMDC / BDDC) they differentiate to create the
• mononuclear phagocyte system (MPS) / macrophage system : the collection of cells consisting of macrophages and their precursors (blood monocytes and their precursor cells in bone marrow). The term has been proposed as a replacement for reticuloendothelial system, which does not include all macrophages and does include other unrelated cell types
• reticulo-endothelial system (RES) : a group of cells having the ability to take up and sequester inert particles and vital dyes; it includes macrophages and macrophage precursors; specialized endothelial cells lining the sinusoids of the liver, spleen, and bone marrow; and reticular cells of lymphatic tissue (macrophages) and of bone marrow (fibroblasts)
• immature Langerhans cell (LC) in the stratum spinosum of the epidermis (Langerans Paul; Ueber die Nerven der menchlichen Haut Virchow Arch. (Pathol.Anat.) 44:325-327 (1868)) : CD1a⁺11c⁺14⁺34⁺68⁺83^-86^-CLA+CD162 / PSGL-1⁺208 / LAMP3^-CCR7^-. Unlike other tissue-resident DCs, which must be replenished by bone-marrow-derived precursors that differentiate into immature DCs, Langerhans cells can self renew in the skin^ref. However, tissue inflammation elicits the recruitment of circulating DCs and of monocytes, which can locally differentiate into DCs^{ref1, ref2}.

‡
+ TGF-b (their development is not impaired by GR agonists) :
quiescent Langerhans cell (LC) (CD1a⁺14⁺83⁺207 / langerin⁺, E-cadherin⁺). They contain Birbeck, Langerhans' or vermiform granules / HX bodies (pentalamellar, membrane-bound, rod- or tennis racquet–shaped cytoplasmic inclusions with a central linear, longitudinally striated nucleus, believed to be a part of the Ag-presenting system)


Ag-presenting capability is inhibited by catecholamines through a_1A-, b₁- and b₂-adrenergic receptors, both at local and systemic level.
See also activation of Langerhans cells.
 
• immature interstitial dendritic cell (iDC) : CD1a^-9⁺14⁺34⁺CLA+CD162 / PSGL-1^-68⁺, asubunit of factor XIII. PPARg is upregulated within a few hours after DC differentiation from monocytes and regulates the expression of CD36 — a surface receptor that mediates uptake of apoptotic cells. Treatment of DCs with a PPARg specific agonist induced a phenotypic change in the DCs, including a decrease in the expression of CD1a, an increase in the expression of CD1d (which can present lipid or glycolipid antigens to iNKT cells) and an enhancement of endocytic activity. Reduced numbers of iNKT cells have been associated with the development of autoimmune diseases, and it might be possible to modify autoimmune diseases by enhancing CD1d expression and iNKT activation through the targeting of PPARg^ref.

 
• (von) Kupffer cells / stellate cells of the liver : large star-shaped or pyramidal cells with a large oval nucleus and a small prominent nucleolus; they line the walls of the sinusoids of the liver.
• vermiform bodies : peculiar sinuous invaginations of the plasma membrane of Kupffer cells of the liver, having a central linear density between parallel membranes and a faint transverse striation; similar structures are seen in macrophages of certain organs and in the Langerhans cells of the epidermis.
• lamina-propria dendritic cells (LPDCs) : CD8a^-11b^-11c⁺ produce high levels of IL-23 in response to the higher concentration of bacteria in the crypts of the distal intestine than the proximal intestine, giving the distal small intestine a predisposition to chronic inflammation such as the T_h1-cell-mediated Crohn's disease, which occurs most often in this part of the gut in humans. However in most mouse models of intestinal inflammation the main pathology occurs in the caecum and colon, and not in the distal small intestine.
• alveolar macrophages (AM) / dust cells in lungs. 70% of the alveolar macrophages come from division in the lungs, whereas 30% come from monocytes.
• microglial cells / Hortega cells / microgliocytes in central nervous system (CNS). The professional APCs of the CNS are the parenchymal microglia and the perivascular cells^{ref1, ref2}, both of which are of myeloid origin and migrate to the CNS during development^ref. The parenchymal microglia have recently been characterized as myeloid progenitor cells that can differentiate into macrophage-like cells expressing CD11b (integrin a_M chain) or dendritic-like cells expressing CD11c (integrin a_x chain) if stimulated with M-CSF or GM-CSF, respectively^ref. In another study, CD11c⁺ cells were isolated from inflamed and normal brain and supported the proliferation of allogeneic T cells that have characteristics different from allogeneic T cells stimulated by CD11b⁺ cells. It has been suggested that myeloid-derived microglia progenitor cells might differentiate into immature dendritic cells (iDCs) in the presence of GM-CSF or sequentially to fully mature DCs with CD40 ligation and that they differentiate into macrophages in the absence of GM-CSF^ref. Nonetheless, it is still unclear whether certain microglia progenitors in the CNS differentiate more effectively to CD11c⁺ cells and whether they migrate to secondary lymph nodes to induce brain-specific T-cell activation. It has become clear that microglia can serve as APCs for Ab-reactive T cells and, in turn, T cells themselves can influence microglial differentiation^{ref1, ref2}. Although microglial activation occurs in inflammatory, degenerative and neoplastic central nervous system (CNS) disorders, its role in pathogenesis is unclear. Ganciclovir treatment of organotypic brain slice cultures derived from CD11b-HSVTK mice (which express HSVTK in macrophages and microglia) abolished microglial release of nitrite, proinflammatory cytokines and chemokines. Systemic ganciclovir administration to CD11b-HSVTK mice elicited hematopoietic toxicity, which was prevented by transfer of wild-type bone marrow. In bone marrow chimeras, ganciclovir blocked microglial activation in the facial nucleus upon axotomy and repressed the development of experimental autoimmune encephalomyelitis. Microglial paralysis inhibits the development and maintenance of inflammatory CNS lesions. The microglial compartment thus provides a potential therapeutic target in inflammatory CNS disorders. These results validate CD11b-HSVTK mice as a tool to study the impact of microglial activation on CNS diseases in vivo^ref.
• osteoclasts in bone (macrophage syncitia)
• synovial cells A in synovia
• pleural macrophages in pleural cavity
• peritoneal macrophages in peritoneal cavity
• mesangial cells / intercapillary cells in renal glomerules
• bone marrow histiocytes in bone marrow
• thymic dendritic cells (TDC) in thymus medulla (involved in self tolerance) :
• CD1a⁺1b⁺11b^-11c⁺45RO^lo (majority)
• CD1a⁺1b⁺11b⁺11c^hi45RO^hi (minority)
• interdigitating cells : APCs cells found in the T-dependent (parafollicular) areas of the deep cortex of lymph nodes and spleen and having numerous surface processes that interdigitate with adjacent lymphocytes; the surface of these cells contains a MHC Ia antigen that causes T cells to cluster.
• spleen sinus histiocytes / splenic dendritic cells (SDC) (CD11b⁺11c^-MARCO^hi) in spleen
• marginal zone (MZ) metallophilic macrophages (MMM), detected by the antibody MOMA1.
• marginal zone (MZ) macrophages (MZM), detected by the antibody ERTR9.
• Hofbauer cells : large, globular cells filled with vacuoles and large spherical nuclei, which are found in the connective tissue core of the chorionic villi of the placenta; they are probably macrophages
• tart cell : a macrophage or monocytoid reticuloendothelial cell that contains a phagocytized nucleus with well preserved nuclear structure; the phagocytized nucleus, as distinguished from an LE cell inclusion, shows an intact chromatin pattern, chromatin that is more dense and tends to become vacuolated, and is frequently smaller than that in a true LE cell.
vermiform bodies : peculiar sinuous invaginations of the plasma membrane of Kupffer cells of the liver, having a central linear density between parallel membranes and a faint transverse striation; similar structures are seen in macrophages of certain organs and in the Langerhans cells of the epidermis.
See also activation of pDC1 to DC1.
• CFU-Eos
+ GATA1, G-CSF, GM-CSF, IL-3, IL-5 / Eo-CSF :
• eosinophil promyelocyte


• eosinophil metamyelocyte


• eosinophil band


• eosinophilic polymorphonucleated (PMN) granulocyte / eosinophil (CD5^-9⁺13⁺19^-23 / FceRII⁺32 / FcgRII⁺35 / CR1⁺43^hi46⁺48⁺68⁺69⁺89⁺153 / 30L⁺244^+refPAR-2⁺PAR-3⁺CCR1⁺CCR2⁺CCR3⁺PAFR⁺TLR4 greater than TLR1, TLR7, TLR9, and TLR10 greater than TLR6^ref. 3÷6 days in bone marrow => average life in blood 6÷12 hrs (t_1/2 = 30') => average life in tissues : some days. Normal blood concentration : 0.08÷0.32 ^. 10⁹ / weight kg ; 0.044÷0.452 ^. 10³ / mL blood ; 0.016÷0.064 % total blood cells ; 1÷4 % total WBCs. Localized mainly in tissues as G-I tract, skin and lungs, at ~ 100-fold higher than plasma concentration : they can recirculate. They are usually 9 to 15 µm in diameter. Granules stain a bright reddish-orange with Wright's or Giemsa stains. The nucleus contains one to three lobes. The chromatin pattern is coarse and clumped. The cytoplasm is abundant with a full complement of bright reddish-orange specific granules. They have eosinophil granules (one of the coarse round granules that stain with eosin and are found in eosinophils) :
• primary / azurophilic / aspecific granules (same content as for primary granules of neutrophils)
• secondary / pseudobasophilic / specific granules (same content as for secondary granules of neutrophils, minus alkaline phosphatase, plus
• p9,000^{Arg-rich major basic protein (MBP)} : a heparan sulfate proteoglycan (HSPG) with pI = 11.4
• major basic protein homolog (MBPH) : a heparan sulfate proteoglycan (HSPG) with pI = 8.7 but effects similar to MBP in cell killing and stimulation assays for neutrophil (O₂^- production and IL-8 release) and basophil (histamine and LTC₄ release), but usually with reduced potency, indicating that the high net positive charge of MBP is important but not essential for biological activity.
• paralog RNases
• eosinophil-derived neurotoxin (EDNT) / eosinophil protein X (EPX) / RNase A family, 2 inactivates retrovirusesin vitro
• eosinophil cationic protein (ECP) / RNase A family, 3 kills bacteria in vitro
They arose by gene duplication some 30 million years ago in an African primate that was ancestral to humans and Old World monkeys. The pair of proteins are relatives of digestive ribonuclease in artiodactyls (Cetartiodactyla), created 40 million years ago in Oligocene, a period of global trauma when ruminant digestion first emerged, to degrade the RNA from bacteria growing in the rumen.
• phospholipase D (PLD)
• histaminase / diamine oxidase
• eosinophil peroxidase (EPO / EPo) has different substrate specificity than neutrophil one)
Eosinophils degeneration produces Charcot-Leyden crystals / asthma crystals, consisting of eosinophil lysophospholipase related to galectin family of b-galactoside binding proteins.
Eosinophil products cause inhibition of kinocilia and shedding of respiratory epithelium, but histaminase, arylsulfatase, phospholipase D, and eosinophil lysophospholipase are considered to act on a negative feedback mechanism in type I hypersensitivities through inactivation of chemical mediators (SRS-A and histamine).
See also activation of eosinophils.
Leptin is a survival cytokine for human eosinophils^ref

Segmented eosinophil
• CFU-Baso
+ IL-3, IL-4 :
• basophil myelocyte


• basophilic granulocyte / basophil / mast leukocyte (CD5^-9⁺11b⁺13⁺19^-43^hi45RO⁺46⁺68⁺w125⁺ MHC II^- CCR1⁺CCR2⁺CCR3⁺CCR4⁺CXCR3^-). Basophils are the smallest circulating granulocytes, averaging 10 to 15 µm in diameter. The nucleus to cytoplasm ratio is about 1:1, and the nucleus is often unsegmented or bilobed, rarely with three or four lobes. The chromatin pattern is coarse and patchy, staining a deep blue to reddish-purple. The cytoplasm is a homogenous pale blue, but this is often obscured by the large dark granules. Each one has specific granules containing :
• histamine
• heparin
• ECF-A
• SRS-A
and ~ 5 ^. 10⁵ FceRI / _cell. Normal blood concentration : 0÷0.008 ^. 10⁹ / kg_{body weight} ; 0÷0.113 ^. 10³ / mL blood ; 0÷0.016 % total blood cells ; 0÷1 % total WBCs. Average life in blood : 3 days.  They can be distinguished from mast cells thanks to positive reaction to 2D7 and BB1 mAbs, which bind to an unknown p72-76 and basogranulin, respectively. They also produce :
• IL-3
• IL-5
• IL-8 / CXCL8 / NCF
• IL-13
• GM-CSF
Basophil preparations constitutively express TLR2, TLR4, TLR9 and TLR10 mRNAs (TLR4 > TLR2 >> TLR9, TLR10). Although TLR mRNA expression in basophils was generally less prominent compared with those in neutrophils and monocytes, basophils expressed significantly higher levels of TLR2 and TLR4 mRNA than eosinophils. Various TLR ligands (Pam₃Cys-Ser-Lys₄, poly I:C, lipopolysaccharide, R-848, CpG DNA) were tested, but none affected the expression level of adhesion molecule CD11b or the viability of freshly purified basophils. On the other hand, when basophils were pretreated with IFN-g before stimulation with TLR ligands, only the TLR4 ligand, lipopolysaccharide, upregulated CD11b expression. However, the surface levels of TLR2 and TLR4 on the interferon-gamma-treated basophils showed no obvious changes. These results suggest that TLR4 on basophils may be involved in the pathogenesis of infection-induced exacerbation of allergic inflammation by modulating basophil functions^ref
See also activation of basophils.

Segmented basophil :


• ? : in adult hematopoiesis, a committed mast cell progenitor has not yet been identified in any species, nor is it clear at what point during adult hematopoiesis commitment to the mast cell lineage occurs. In adult mouse bone marrow, a cell pppulation characterized as Lin^-c-Kit⁺Sca-1^-Ly6c^-FcRI^-CD27^-b₇⁺T1/ST2⁺ gives rise only to mast cells in culture and can reconstitute the mast cell compartment when transferred into c-kit mutant mast cell-deficient mice. In addition, these adult mast cell progenitors are derived directly from multipotential progenitors instead of, as previously proposed, common myeloid progenitors or granulocyte/macrophage progenitors^ref.
+ SCF (while IL-4 induces down-regulation of activating receptors and promotes cell death by inducing proteolytic processing of STAT6 to a dominant negative isoform), PU.1, and GATA2 :
• immature mast cell / mastocyte / labrocyte (CD117 / c-Kit⁺). No granules. Released in bloodstream

‡
• mature mast cell / mastocyte / labrocyte (CD32 / FcgRIIb2⁺88 / C5aR⁺154 / 40L / gp39⁺88 / C5aR⁺117 / c-Kit⁺) (from the Deutsch mastung = to chew, due to the wrong impression that granules were residual bodies). Each mast cell has about 200-500 ...
• primary / azurophilic / basophilic / aspecific granules (same content as for neutrophilic granulocytes)
• secondary / metacromatic / specific granules
• histamine
• proteoglycans
• heparin
• ECF-A
• protease inhibitor trypstatin (a fragment of inter-alpha-trypsin inhibitor light chain (ITI-LC) / a₂-macroglobulin)
• mast cell tryptases (skin tryptase 1 / b₁ and b₂ (bII and bIII allelic variants) >> a, d₁ / mMCP-7-like, g₁ (2 allelic variants), e) (not expressed in bowel submucosal mast cells)
• chymase 1
• in certain species, such as the rat and mouse, serotonin

They proliferate in :
• mucosae (mucosal mast cells (MMC) : in the lamina propria of lung, bowel mucosa and submucosa, mammary gland, but also frequent in the epithelial layers of composed epithelia)
• lymph nodes
• epidermis
• around venulae of deep tissues
See also activation of mast cells.
In bone marrow they are found near bone and then migrate into the blood vessels.
Leukocyte or white blood cell count : determination of the number of leukocytes in a unit volume of blood, usually after the erythrocytes have been lysed and the blood has been diluted; it may be done either manually with a hemacytometer or electronically
• differential blood or leukocyte count : a leukocyte count that calculates the percentages of different types
• filament-nonfilament count : in the differential leukocyte count, determination of the number of juvenile and mature leukocytes
• total lymphocyte count (TLC) : a test that may be useful as an indicator of nutritional status and outcome.
• total leukocyte count (WBC) : 0.8 ^. 10⁹ / weight Kg ; 4.4÷11.3 ^. 10³ / mL blood ; 1.6 % total blood cells
• lobular index (LI) = (neutrophils + eosinophils) / (lymphocytes / monocytes)
blood cell count : determination of the number of formed elements in a cubic millimeter of blood; it may be a complete blood count or it may measure just one of the formed elements. Methods include manual counts with a hemacytometer and automated counts with a flow cytometer, a Coulter counter, or other means.
• complete blood count (CBC) / full blood count (FBC) : a series of tests of the peripheral blood, including the erythrocyte count, erythrocyte indices, leukocyte counts, and sometimes platelet count.
Circadian rhythms in blood cell concentrations :


Antigen expression on peripheral blood cells :

antigens	erythrocytes	platelets	neutrophils	B lymphocytes	T lymphocytes	monocytes
A, B, H	+++	++/(+)	-	-	-	-
I	+++	++	++	-	-	-
Rh	+++	-	-	-	-	-
K	+++	-	-	-	-	-
HLA class I	-/(+)	+++	+++	+++	+++	+++
HLA class II	-	-	-/+++(on activated cells)	+++	-/+++(on activated cells)	+++
GPIIb/IIIa	-	+++	(+) (GPIIIa (b3) in association with an alterative a chain (av)	-	-	-
GPIa/IIa	-	+++	-	-	++	-
GPIb/IX/V	-	+++	-	-	-	-
CD109	-	(+)/+++++(on activated cells)	-	-	-/++(on activated cells)	(+)

• arterial blood gases (ABG)
• P_O2
• P_CO2
• plasma electrolytes
• plasma cations
• sodiemia / natremia = [₁₁Na⁺]_plasma = 136-145 mEq/L
• potassiemia / kalemia = [₁₉K⁺]_plasma = 3.5-5.3 mEq/L
• calcemia = [₂₀Ca]_plasma = 8.2-10.5 mg/dL = 2.10-2.55 mmol/L (higher in babies). Add 1 mg/dL for every g/dL of albumin below 4 g/dL
• [free Ca²⁺] = 4.8 mg/dL = 1.13-1.32 mmol/L
• plasma protein-bound calcium : 50% = 0.8 ^. [albumin (g/L)] + 0.2 ^. [globulins (g/L)] + 3.
• magnesemia = [₁₂Mg²⁺]_plasma = 1.4-2.2 mEq/L = 0.8-1.3 mOsm/L_H2O
• [free Mg²⁺] : 50%
• compound magnesium : 15%
• plasma protein-bound calcium : 30%
• sideremia = [₂₆Fe²⁺]_plasma = 35-141 mg/dL = 9.0-26.9 mmol/L (higher in males)
• cupremia = [₂₉Cu⁺]_plasma = 100-200 mg/dL
• lithemia = [Li⁺]_plasma = 0.5-1.5 mEq/L
• plumbemia = [Pb⁺]_plasma < 50 mg/dL
• plasma anions
• chloremia = [₁₇Cl^-]_plasma = 95-111 mEq/L
• iodemia = [₅₃I^-]_plasma = 1 mg / dL
• inorganic phosphoremia = [phosphorus]_plasma = 2.5-4.68 mg/dL or 0.75-1.5 mmol/L (values are doubled, up to 6 mg/dL, in babies before age 1; higher in menopause)
• NaHPO₄^- and HPO₄^2- : 75%
• H₂PO₄^- : 10%
• plasma protein-bound calcium : 12%
Circadian rhythm with nadir between 9 and 12 a.m., plateau in afternoon and peal after midnight
• sulforemia = [SO₄^2-]_plasma = 0.5 mOsm/L_H2O
• bicarbonatemia = [HCO₃^-]_plasma =
• 23-27 mM in arterial blood (radial > femoral > brachial artery)
• 26-30 mM in venous blood
• plasma proteins (7 % ^v/_v) (1.2 mOsm/L_H2O ; 6.0-8.4 g / dL in serum + 0.3 g / dL of fibrinogen = 7.2 g / dL). In serum protein electrophoresis, they become distributed in the following arrangement:

(+) anode
• prealbumins
• transthyretin  / TBPA
• albumins (52-68%)
• serum albumin (3.5÷5.2 g / dL; t_1/2 = 20 hrs)
• CPK1
• globulins (2.3-3.5 g/dL)
• a₁-globulins (1.5-7.2%)
• orosomucoid / a₁ acid gp 1
• orosomucoid / a₁ acid gp 2
• a₁-antitrypsin / a₁-antiplasmin
• a₁-microglobulin
• a₁-antichimotrypsinogen
• a₁-FP
• LDH₁ / LDH_A
• a-lipoproteins / HDL
• a₂-globulins (6.8-14%)
• fast a₂-globulins
• ceruloplasmin. Normal plasma concentration : 27-37 mg/dL = 1.8-2.5 mmol/L
• fast hepatic AlkP
• a₂-macroglobulin
• Epo
• transcortin / CBG
• haptoglobins : a 100,000-dalton plasma glycoprotein with a electrophoretic mobility. It is synthesized primarily by hepatocytes but released also by specific granules of neutrophils^ref. Hp exerts a broad range of anti-inflammatory activities and acts indirectly as a bacteriostatic agent and an anti-oxidant by virtue of its ability to irreversibly bind free hemoglobin (Hb), and facilitate its immediate clearance by macrophages in the RES in liver, preventing loss of free hemoglobin in the urine. Haptoglobin levels are decreased by hemolysis and increased owing to increased synthesis in conditions resulting in extensive tissue damage and necrosis. Haptoglobin has 2 major genetic variants, designated Hp 1 and Hp 2, that create 3 phenotypes (1-1, 2-1 and 2-2). Normal plasma concentration : 40-336 mg/dL (0.3-2 g/l); biological half-life : 5.4 days^ref. Serum Hp concentration is associated with body mass index (BMI) via white adipose tissue IL-6-mediated hepatic synthesis. The liver is the predominant site of Hp synthesis, and the contribution of extrahepatic synthesis to the serum Hp concentration seems limited^{ref1, ref2}. Hp 2-2 phenotypes showed higher oxidized low-density lipoprotein concentrations, compared with other phenotypes, suggesting a higher oxidative stress in Hp 2-2 phenotypes^ref.
• haptoglobin-related protein (Hpr) is a primate-specific plasma protein associated with apolipoprotein L-I (apoL I)-containing high density lipoprotein (HDL) particles shown to be a part of the innate immune defense. Despite the assumption hitherto that Hpr does not bind to hemoglobin, recombinant Hpr binds hemoglobin as efficiently as haptoglobin (Hp). However, in contrast to Hp, Hpr did not promote any high- affinity binding to the scavenger receptor CD163. Binding of hemoglobin to circulating native Hpr incorporated into the HDL fraction was indicated by hemoglobin-affinity precipitation of plasma Hpr together with apoL I. In conclusion, plasma has two high-affinity haemoglobin-binding haptoglobins instead of one, but only Hp hemoglobin complexes are efficiently recognized by CD163. Circulating Hpr-bound hemoglobin should therefore be taken into consideration when measuring 'free' plasma hemoglobin. Furthermore, Hpr-bound hemoglobin might contribute to the biological activity of the circulating apoL-I/Hpr-containing HDL particles^ref.
• prothrombin
• antithrombin III / heparin cofactor I
• pre b-lipoproteins / VLDL
• slow a₂-globulins
• angiotensinogen
• a₂-antiplasmin 1
• a₂-antiplasmin 2
• antithrombin III / heparin cofactor I
• slow hepatic AlkP
• bone-specific alkaline phosphatase (bALP) (2-15 mg/L)
• osteocalcin / bone Gla protein (BGP) (6.8-34 ng/mL; 10.7-37 ng/mL in males and 8.8-39.4 ng/mL in females)
• b-globulins (9-15%)
• b₁-globulin (7-10%)
• transferrin. Normal plasma concentration :  210÷360 mg / dL
• b₁-gp / SP1-gp / PAPP-C
• b-lipoproteins / LDL
• salivary amylase a_1A
• salivary amylase a_1B
• salivary amylase a_1C
• b₂-globulins (3-6%)
• C3
• C3c (90-180 mg/dL)
• C4 (10-40 mg/dL)
• renal AlkP
• CPK2
• b₂-microglobulin (200-2,000 ng/mL)
• b₂-gp I
• LDH₃/ LDH_C / LDH_x (testis)
• hemopexin
• some monomeric IgA
• g-globulins (10-23%)
• fast g-globulins
• some monomeric IgA
• LDH_x
• fibrinogen ABg (only if plasma is used instead of serum !)^ref circulates in the plasma at a concentration of 2 g/L to 4 g/L with a half-life of approximately 4 days and is a modest acute-phase reactant, increasing in concentration in response to most forms of tissue injury, infection, or inflammation. The native 340-kDa molecule is a disulfide-bonded homodimer, each protomer composed of 3 nonidentical disulfide cross-linked polypeptide chains (Aa, Bb, and g) that are synthesized under the control of 3 genes. Liver is the source of at least 98% of the circulation fibrinogen^ref. See also fibrinogen Aa chain amyloidosis and congenital hypofibrinogenemia
• magroglobulin / pentameric IgM
• IgD
• LDH₄ / LDH_D
• pancreatic amylase a_2A
• pancreatic amylase a_2B
• placental isozyme of alkaline phosphatase (ALPP) / Regan isozyme
• placental-like 2 isozyme of alkaline phosphatase (ALPPL2)
• slow g-globulins
• CRP < 5 mg/L
• plasminogen
• IgG
• k chain. Normal plasma concentration : 3.3-19.4 mg/l
• l chain. Normal plasma concentration : 5.7-26.3 mg/l
• k/l ratio. Normal plasma concentration : 0.26-16.5
• LDH₅
• LDH₆
• CPK3
• intestinal isozyme of alkaline phosphatase (ALPI)
• chylomicrons
(-) cathode
• a-globulins / g-globulins (A/G) ratio : the ratio of albumin to globulin in the blood serum, plasma, or the urine in various types of renal or liver disease = 1.1-2.4. It is being replaced by quantitiative measurement of specific serum proteins
• serum hemoglobin : 2-3 mg/dL = 1.2-1.9 mmol/L.
Plasma enzymes :
• specific (coagulation factors, ceruloplasmin, serum acetylcholinesterase)
• aspecific
• secretory enzymes (proteases, glycosylases, lipases)
• intracellular metabolism enzymes (release of mitochondrial enzymes marks more severe damage) : if the enzyme is contained within blood cells, avoid cytolysis of the blood sample !
• ubiquitous enzymes (glycolysis enzymes, TCA cycle enzymes, pentose-phosphate pathway, amino acid metabolism enzymes)
• tissue- or organ-specific enzymes : multiple forms of enzymes (creatine, glucuronides, urea)
• isozymes :
• from paralogous genes
• monomers
• heterooligomers
• codominant allozymes
• alternative splicing enzymes
• posttranslational modifications or molecular forms
The features used for dosing are :
• structure :
• electrophoretic mobility
• denaturation
• chromatographic behaviour
• pI
• antigenicity
• catalytic activity
• specificity for substrate
• specificity for inhibitors
• activity according to buffer solution

enzyme	blood concentration	multiple forms	assay	distribution	increased in increased production decreased excretion (bile, urine, RES) increased permeability or necrosis (for intracellular enzymes)	decreased in
alkaline phosphatase (AlkP / ALP) liver/bone/kidney (tissue non-specific) isozyme of ALP (ALPL)	100-300 IU/L at 37°C (varies with age (peak at birth, fall at age 5, lesser peak at age 12 and fall at age 20) and temperature)	slow hepatic AlkP (normal)	substrates for spectrophotometry :  b-glycerophosphate (Bodansky) Bodansky unit : the quantity of alkaline phosphatase that liberates 1 mg of phosphate ion from glycerol 2-phosphate in 1 hour at 37°C and under other standardized conditions. pyrophosphate (King-Armstrong) King-Armstrong unit : the amount of phosphatase that liberates 1 mg of phenol from an excess of disodium phenylphosphate under defined conditions; alkaline phosphatase can be measured under alkaline conditions and acid phosphatase under acidic conditions PNPP (Bessey-Lowry) + Mg2+ =pH 9.8=>	hepatocytes (also in bile)	cirrhosis, obstructive jaundice, liver metastases, cholestasis, acute and chronic hepatitis, occupation syndromes, partial choledocholithiasis	scurvy magnesium deficiency infantile hypothyroidism cachexia congental hypophosphatemia  Fanconi syndrome renal failure idiopathic acidosis  bone radiotherapy
		bone AlkP (bALP) (normal) (2-15 mg/L)		osteoblasts => values related to total bone mass, higher in males	tumours, rickets, Paget's disease, bone fractures, osteomalacia, barbiturates, hyperparathyroidism; not increased in osteoporosis or multiple myeloma
		intestinal AlkP (normal) : neuraminidase-insensitive thanks to internal Sia residue => constant pI		enterocytes only in 0 or B blood group individuals => also in faeces	after meals, IBDs, chronic diarrhea, intestinal tuberculosis, cirrhosis or hepatitis-related ascitis
		placental alkaline phosphatase (PLAP) / heat-stable alkaline phosphatase (HSAP) / secreted embryonic alkaline phosphatase (SEAP) (normal) : the only form not inhibited by EDTA and 100% stable at 56°C for 10'		placenta	since formation of placenta (pregnancy wk 14-16) to wk 1 after delivery; preeclampsia, multiple pregnancies
		fast hepatic or biliary AlkP (pathological)		hepatocytes	as for slow isozymes, plus increased synthesis in HCC and liver granulomata (sarcoidosis)
		Regan carcinoplacental AlkP (pathological)			various carcinomas (pleura, lungs)
		renal AlkP  (pathological)		proximal renal tubule (also in urine)	renal transplant recipients
g-glutamyl transferase (gGT) (heterodimer)	6-28 IU/L at 25°C  9-50 IU/L at 37°C	1  2  3  4  5 (pathological)  Molecular forms are not determinated usually	spectrophotometry  N-g-glutamyl-p-nitroanilide  N-g-glutamyl-naphthylamide	kidney, pancreas, liver, intestine, lungs, spleen, thyroid, myocardium, many other tissues other than skeletal muscles	liver diseases (hepatitis, metastases), cholestasis (higher specificity thank AlkP, higher sensitivity than 5'-nucleotidase and Leu-AP)  other (pancreatitis, diabetes mellitus, pancreatic carcinoma, AMI, renal or cerebral neoplasia, inducer drugs (barbiturates, antiepileptic drugs), infectious mononucleosis,hyperthyroidism	asymptomatic condition
5'-nucleotidase	0-1.6 IU/L at 37°C		AMP + H2O + Mg2+ + Mn2+ =pH 7.5=> Ado + Pi + NH4+MoO4 => violet compound red with spectrophotometry at 630-640 nm; repeat assay with inhibitors (Ni2+, Zn2+) => difference is activity of 5'-nucleotidase only	liver, brain, muscle, kidney, lung, bone, thyroid, endothelium	liver diseases (cholestasis, occupation syndromes, hepatitis)
aspartate transaminase (AST) / serum glutamate-oxalate transaminase (SGOT) : cytosolic and mitochondrial (80%)	17-22 IU/L at 25°C  25-40 IU/L at 37°C		Asp + aKG + PPi (not all molecules had it added) =AST=> Glu + OAA =+NADH=MDH=> malate + NAD+	myocardium, brain, liver, fatty tissue, gastric mucosa, skeletal muscle, kidney, and less pancreas, spleen, testes, RBCs	AMI (after 8-12 hrs, peak after 36 hrs, normal in 4-7 dd), myocarditis (not in angina pectoris)  hepatitis and cirrhosis (1-4 wks before haundice, 100-fold peak after 7-10 days, normal after 4-5 wks)  pulmonary and renal infarction  myopathies
alanine transminase (ALT) / serum glutamate-pyruvate transaminase (SGPT)	15-18 IU/L at 25°C		Ala + aKG + PPi (not all molecules had it added) =ALT=> Glu + Pyr =+NADH=LDH=> lactate + NAD+ Karmen unit : the amount of transaminase that under specified conditions will cause a change of 0.001 in the absorbance of NADH when measured at 340 nm in a 1 cm light path.	liver and less in kidney, myocardium, skeletal muscles, pancreas, spleen	hepatitis and cirrhosis (De Ritis' ratio = [AST]/[ALT] = 1, then < 1) mtAST/(mtAST + cAST) > 0.8 and [AST]/ALT] > 2 in AMI, pulmonary and renal infarction [AST] > [AlkP] => hepatitis [AST] < [AlkP] => ostructive jaundice
lactate dehydrogenase (LDH) separated with electrophoresis, nonsandwich IRMA precipitation, tetrazolium salts, or densitometry; it is heat-unstable and inhibited by guanidine thiocyanate  LDH1 / LDHA (skeletal muscle) LDHA-like LDHA-like 1 (seminoma) LDHA-like 2 LDHA-like 3 LDHA-like 4 LDHA-like 5 LDH2 / LDHB (including K6E fast isozyme; heart) LDHB-like 1	< 120-240 IU/L at 25°C  < 450 IU/L at 37°C	LDH1 / aKBDH = H4 (at 25°C it also catalyzes aKBut => a-hydroxybutyrate)		myocardium, kidney, RBC (18-33%)	AMI (> 82%; after 12-24 hrs, peak after 36 hrs; normal after 7-10 days), intravascular hemolysis, tumors	11 different mutationsref1, ref2, ref3, ref4, ref5, ref6, ref7, ref8, ref9 (M. Kamada, K. Fujita, I. Sakurabayashi et al., A family with a case of deficiency of lactate dehydrogenase H-subunit. Seibutsu Butsuri Kagaku 36 (1992), pp. 161–164) : 3 base deletion (AAT) at codon 220 of exon 5, which caused a deletion of one asparagineref
		LDH2 / H3M1		myocardium, kidney, RBC, WBC (28-40%)	AMI (> 82%; after 12-24 hrs, peak after 36 hrs; normal after 7-10 days; lesser increase than LDH1), intravascular hemolysis, pulmonary infarction, tumors
		LDH3 / H2M2		liver, muscles, WBC (18-30%)	pulmonary infarction, tumors
		LDH4 / H1M3		liver, muscles, WBC (6-16%)	hepatopathies, tumors
		LDH5 / M4		skeletal muscles, liver (2-13%)	traumas, DMD > 11-24%, hepatopathies, tumors
		LDH6 / LDHx		testes, hypoxic tissues	renal ischemia and pyelonephritis (not in cystitis), germ cell tumors
creatine phosphokinase (CPK / CK) : cytosolic and mitochondrial macro-CPK :  I :  BB + IgA  BB + IgG II : aggregates of mtCPK)	at 25°C :  males : 10-70 mIU/L females : 10-60 IU/L at 37°C :  males : 24-195 IU/L females : 24-170 IU/L	CPK1 = BB (oncofetal)	Oxidation of thiols, which reduces activity by 50% in 4-6 hrs at RT can be prevented by glutathione. Spectrophotometric assay with adenylate kinase inhibitors (Mg2+, AMP, diadenosine monophosphate, N-acetyl-cystein). Isozymes can be dosed with sandwich ELISA	brain, smooth muscle (< 1%)	cerebral ischemia, encephalitis, various neoplasms, epilepsy, psychosis
		CPK2 :  MB1 (1 lysine residue) MB2		myocardium (< 3%)	AMI (after 4 hrs, 8-fold peak in 24 hrs, normal after 2 dd; [MB2]/[MB1] increases after 90'); newborns, reject of heart transplant, after muscular damage or disease
		CPK3 :  MM1 (2 lysine residues) MM2 (1 lysine residue) MM3		myocardium and skeletal muscles (97%)	physical exercise, intramuscular injections, neuroleptic malignant syndrome,  trauma and muscle dystrophies (expecially DMD, before onset of symptoms, decreases during time due to replacement with fibroadipous tissue), myositis, dermatomyositis, AMI ([MM3]/MM4] increases after 3 hrs), hypothyroidism (increased membrane permeability) (not in nephropathies, hepatopathies, hemopathies, pulmonary infarction; decreased in hyperthyroidism)
aldolase	0.5-3.1 IU/L at 25°C	A  B  C	Fru-1,6-bisP => GA3P + DHAP =+NADH=> NAD + glyceraol-3-phosphate	skeletal muscle, myocardium, liver and brain	AMI, viral hepatitis, myoglobinuria (not in myasthenia gravis and obstructive jaundice)
a-amylase (ALS) / diastase	120-360 IU/L at 37°C	pancreatic amylase P1 (deglycosylated) P2 P3 (-AsnGln)	Somogyi saccharometric method : maltopentose => maltotriose + maltose => 5 Glc =hexokinase => 5 Glc-6-P + 5 NADP+ => 5 6-phosphogluconolactone + 5 NADPH (l = 340 nm)  Somogyi unit : that amount of amylase that will liberate reducing equivalents equal to 1 mg of glucose per 30 minutes under defined conditions. chromogenic method : PNP-maltohexose => 2-PNP-maltotriose + H2O =a-glucosidase, basic pH=> Glc + PNP (l = 405 nm)  starch => glucose or +I2 => amylose(I)n blue (l = 560-600 nm)	pancreas >> lungs, testes, ovaries	pancreatic disease : pancreatitis acute pancreatitis (rise after 2-12 hrs, peak after 24 hrs (urinary peak after 48 hrs), normal in 3-5 days) chronic pancreatitis: ductal obstruction complications of pancreatitis pancreatic pseudocyst pancreatogenous ascites pancreatic abscess pancreatic necrosis pancreatic trauma pancreatic carcinoma nonpancreatic disorders :  renal failure "tumor" hyperamylasemia carcinoma of the lung carcinoma of the esophagus breast cancer, ovarian cancer macroamylasemia burns acidemia, expecially diabetic ketoacidosis (DKA) pregnancy renal transplant traumatic brain injury (TBI) drugs: opiate (morphine)-induced spasms of Oddi's sphincter other abdominal disorders biliary tract disease: cholecystitis, choledocholithiasis intraabdominal disease perforated or penetrating peptic ulcer deepened into pancreas intestinal obstruction or infarction ruptured ectopic pregnancy in uterine tube peritonitis aortic aneurysm chronic liver disease postoperative hyperamylasemia	chronic pancreatitis with pancreatic failure
		salivary amylase or ptyaline (inhibited by lecithine)  S1 S2 (deglycosylated) S3 (-AsnGln)		salivary glands	parotitis, irradiation sialadenitis, maxillofacial surgery, sialolithiasis, renal failure, macroamylasemia (polymers + IgA => decreased clearance)
lipases (LPS)	190 IU/L at 25°C  200 IU/L (0.05-1 conventional units) at 37°C	pancreatic lipase (acts on sn-1 rather than on sn-2)	activated by Ca2+ triolein =pH 8.8=> glycerol + FFAs => turbidimetry olive oil =3 hrs at pH 8=> glycerol + 3 oleic acid titred with NaOH 0.5 N and thymolphtahalein (virates at pH ?	pancreas and pancreatic ducts	acute pancreatitis, pancreatic carcinoma, tumor or calculus of Vater's ampulla
		lipoprotein lipase (activated by heparin)
cholinesterase		true cholinesterase / acetylcholinesterase (AChE)	hydrolysis of thioesters (inhibted by [ACh] > 10-2 M)  acetylthioCh => acetate + ...  butirrylthioCh => butyrrate + ... ...thiocholine =+ 5,5'-dithiobis-(2-nitrobenzoate) (DTNB, Ellman reagent)=> 5-thio-2-nitrobenzoate (inhibited by citrate, fluoridde, morphine, quinine, alkaloids, organophosphates; spectrophotometry, l = 405-470 nm)	RBCs, lungs, spleen, gray matter of brain (cholinergic synapses)	multiple sclerosis, psychoses, schizophrenia (normal in viral hepatitis, chronic hepatitis, obstructive jaundice, AMIAMI, intestinal malabsorption)	paroxysmal nocturnal hemoglobinuria, autoimmune and newborn hemolytic anemia
	3,000-9,000 IU/L at 25°C	serum cholinesterase, benzoylcholinesterase, butrrylcholinesterase or pseudocholinesterase		liver, pancreas, myocardium, white matter, serum		organophosphate poisoning, liver cirrhosis, acute necrotizing hepatitis, HCC, carriers of atypical allozyme have decreased catabolysis of suxamethonium (succinyldicholine) => anaesthetic apnea (lower Kcat and less inhibited by dibucain)
acid phosphatase (AcP / ACP)	< 11 IU/L at 25°C	very sensitive to L-tartrate (isoforms 2a, 2b and 4)	keep at 4°C with acetate 3 mM (pH = 2) (otherwise decreased activity at 23°C : -30% in 3 hrs, -100% in 3 days). To produce color, the reaction of the ancillary enzyme should be practiced after rising pH with alkaline solution (which also stops reaction) : only then PNP is convertred to quinoid. P-ACP is also dosed with ELISA (as for AlkP) or with subtraction dosing respect to L-tartrate inhibition	granulocytes, pancreas, prostate (but as it flows into seminal fluid, concentration in males and females are roughly the same	metastatic prostatic carcinoma (100-fold increase) (prostatic or osteoclastic isozyme if bone metastases occur: ACPtotal and P-ACP are poorly sensitivity in initial stages, when PSA dosage is preferred), hemocytolysis, sphingolipidoses, Paget's disease, primary and secondary hyperparathyroidism
		moderately sensitive to L-tartrate (isoform 3)		lysosomes (liver, spleen, muscles, stomach, platelets, WBCs)
		L-tartrate resistant acid phosphatase (TRAP) (5a and 5b isoforms)		hairy cell leukemia, osteoclasts, RBCs
lactate			spectrophotometry			2-3 hrs of muscular immobility
pyruvate			spectrophotometry
amino acids			HPLC

• anion gap (AG) = [Na⁺ - (Cl^- + HCO₃^-)]_plasma = 8-16 mEq/L = total charge of plasma proteins
• pH_plasma = - log₁₀[H⁺]_plasma =  pK_a + log₁₀([HCO₃^-]_plasma / [CO₂]_plasma) = pK_a + log₁₀([HCO₃^-]_plasma / (0.03 ^. P_{CO2, plasma})) = (kidney function) / (lung function)
• [H⁺]_{plasma, artery} = 4.0 .10^-5 mEq/L => pH_{plasma, artery} = 7.40 +/- 0.2
• [H⁺]_{plasma, vein} = 4.5 .10^-5 mEq/L => pH_{plasma, vein} = 7.36 +/- 0.2
• [H⁺]_{interstitial fluid} = 4.5 .10^-5 mEq/L => pH_{plasma, interstitial fluid} = 7.35
• H₂O (93 % ^v/_v)
• other plasma molecules (< 1 % ^v/_v) :
• sugars (normally glucose is the only sugar found in blood)
• glycemia = 70÷110 mg / dL = 5.6 mOsm/L_H2O
• fructosaminemia = 205-285 mmol/L
• lipids and related compounds
• triglyceridemia (TG) = 70÷150 mg / dL
• nonesterified fatty acids (NEFA) = 780 M
• total cholesterolemia (T-Ch) < 200 mg / dL in adults ; < 170 mg/dL in babies. On the contrary of TG, T-Ch values are not affected by the diet of the day before sampling.
• in HDL (HDL-Ch) > 35÷50 mg / dL in males ; 45÷70 mg / dL in females. It is measured after chemical precipitation of VLDL and LDL.
• in VLDL (VLDL-Ch) = TG/5. This equation doesn't works in patients with triglyceridemia > 4.5 mmol/L (> 400 mg/dL) or dysbetalipoproteinemia.
• in LDL (LDL-Ch) = T-Ch - (HDL-Ch + VLDL-Ch) = T-Ch - (HDL-Ch + TG/5) (Friedewald formula)
• < 160 mg/dL (desirable in general population)
• < 130 mg/dL (desirable in patients with systemic arterial hypertension)
• < 100 mg/dL (desirable in patients with IHD or equivalent : diabetes mellitus, AAA, lower limb obliterating arteriopathy, cerebrovascular diseases)
• Lp(a) < 30 mg/dl
• apolipoprotein A-I = 95÷230 mg / dL
• apolipoprotein B-48 + B-100 = 55÷65 mg / dL
• other nitrogen-containing compounds :
• azotemia
• ammonemia : 15-55 mmol/L
• uremia = 25÷50 mg / dL = 4 mOsm/L_H2O
• blood urea nitrogen (BUN) = [urea] x 28/60 = 8÷25 mg / dL = 2.9-8.9 mmol/L
• 98% comes from catabolism of dietary proteins
• 2% comes from catabolism of endogenous proteins
• [N]_protein = [protein] / 6.25
• lactacidemia = 10 mg/dL = 0.6-1.8 mEq/L = 1.2 mOsm/L_H2O
• ketonemia < 0.5 mmol/L; hyperketonemia is defined as levels >1 mmol/l, and DKA is defined as levels >3 mmol/l
• homocysteinemia = 5-16 (4.45-12.42) mmol/L (70% bound to proteins). Premenopausal women have approximately 20% lower values than their male counterparts
• oxalemia = 1.53 (0.78- 3.02) mmol/L
• in children : plasma oxalate:creatinine molar ratio = 0.033+/-0.013
• pyruvatemia = 0-0.11 mEq/L
• uricemia = 3-4 mg/dL = 180-240 mmol/L in babies; 4÷8 mg / dL = 180-420 mmol/L in postpuberal males and postmenopausal females ; 3÷7 mg / dL = 360 mmol/L in postpuberal-premenopausal females (varying according to age, height, weight, systemic arterial pressure, renal function, and ethanol consumption)
• aminoacidemia = 2 mOsm/L_H2O
• creatinemia = 0.2 mOsm/L_H2O
• creatininemia = 0.6-1.5 mg/dL in males and 0.6÷1.3 mg / dL in females (CV = 7%)
• other molecules = 4.8 mOsm/L_H2O
• conjugated or direct bilirubinemia = 0-0.4 mg/dL = 0-7 mmol/L
• total bilirubinemia = 0.5÷1.2 mg / dL = 8.5÷20.5 mmol / L
• biliary salts =
• indicanemia : the presence of indican (potassium indoxyl sulfate, formed by decomposition of tryptophan in the intestines, absorbed, conjugated, and excreted in the urine) in the blood.
• hormones
• global plasma parameters
• total plasma osmotic activity, effective osmolarity or tonicity : 208-300 mOsm/Kg_H2O (theoretically 301.2)
• predicted osmotic activity= 2 Na⁺ + Glc + BUN (mmol/L) = 2 Na⁺ (mmol/L) + Glc (mg/dL) / 18 + BUN (mg/dL) / 2.8. Usually difference from measured value is < 10-15 mmol/kg H₂O.
• corrected osmotic activity : 282 mOsm/L
• total osmotic pressure at 37°C : 5443 mmHg
• g granules : a name applied to basophilic granules found in the blood, marrow, and in the tissues.
• humoral amplification systems : a collective term for the four enzyme cascades that serve as amplification and control mechanisms in hemostasis, inflammation, and tissue repair
• complement system
• kallikrein kinin system (KKS) : the system of proteins involved in the production and destruction of kinins, e.g., bradykinin and kallidin. Kinins are cleaved from precursor substances called kininogens by kallikreins and are rapidly destroyed by kininases. Plasma kallikrein circulates as a proenzyme (prekallikrein) and is converted to active form by factor XIIa, which cleaves HMW kininogen, an a₂-globulin, to produce bradykinin
• kininogen : either of 2 plasma a₂-globulins that are kinin precursors, called ...
• high-molecular-weight kininogen (HMWK) / Fitzgerald factor : a kininogen of molecular weight 100,000–250,000 that is split by plasma kallikrein to produce bradykinin
• low-molecular-weight kininogen (LMWK) : a kininogen of molecular weight 50,000–75,000 that is split by tissue kallikrein to produce kallidin.
Kinins cause vasodilation of most vessels but vasoconstriction of the pulmonary bed, and also alter vascular permeability.
• plasma kallikrein is a kinetically favorable activator of prourokinase to urokinase^ref. Urokinase binds to its receptor, uPAR, on the endothelial-cell surface. Since prekallikrein binds to HK, which associates with the same receptor, the conversion of plasminogen to plasmin is efficient and probably represents the in vivo site^ref. Thus, prekallikrein may be an antithrombotic protein by virtue of its role in the fibrinolytic system. The substrate of the KKS HK also displays antithrombotic activity. HK inhibits thrombin-induced platelet activation^ref, and an HK-deficient rat exhibits much more rapid onset of arterial thrombosis following endothelial injury^ref. 2 distinct sequences from domain 3 and domain 4 are each capable of inhibiting thrombin-induced platelet activation, although the affinities and the mechanism are different. Most of the inhibitory activity of domain 3 is in the region coded for by exon of G235-Q292 (IC₅₀ = 0.2 µM)^ref. This sequence competes with thrombin for binding to platelet GPIb. The second sequence in domain 4 is minimally contained in the breakdown product of bradykinin, catalyzed by ACE, bradykinin 1-5 peptide RPPGF^ref. Mice lacking the constitutive BKB2R exhibit decreased risk for thrombosis^ref. The animals have delayed thrombosis in an endothelial-cell photochemical injury model due to local free radical release as well as a prolonged bleeding time compared with mice with normal levels of BKB2R in the same genetic background. plasma angiotensin II elevation could result from increased ACE activity due to the need to metabolize more bradykinin as a result of an indirect effect of the lack of BKB2R. This conclusion reinforces recent evidence that angiotensin II receptors and bradykinin receptors may interact and regulate each other at the level of the receptor^ref
• kininase : an enzyme that destroys the activity of circulating kinins.
• kininase I : serine carboxypeptidase.
• kininase II / peptidyl-dipeptidase A [EC 3.4.15.1] / dipeptidyl carboxypeptidase I / angiotensin-converting enzyme (ACE) : an enzyme of the hydrolase class that catalyzes the cleavage of a dipeptide from the C-terminal end of an oligopeptide; it is a zinc protein found on the luminal surface of vascular endothelial cells in the lungs and other tissues
• coagulation (see also coagulopathies)

Simplified scheme of main interactions (the extrinsic pathway doesn't exist in vivo)
In vivo confocal microscopy movie of thrombus formation : in response to a laser-induced injury of a normal vessel wall in paper-thin rat scrotum, red-labeled platelets and green-labeled tissue factor accumulated within seconds, as expected. In about 20 seconds, blue-labeled fibrin formed and filled in the bulk of the thrombus. In the final analysis, some tissue factor was integrated throughout the clot but, unexpectedly, most of the tissue factor lined the interface between the thrombus and the vessel wall.
• plasma concentrations of coagulation factors :substances in the blood that are essential to the clotting process and hence, to the maintenance of normal hemostasis. They are designated by Roman numerals, to which the notation “a” is added to indicate the activated state. Platelet factors also play a role in coagulation.

international nomenclature	denomination and synonyms	secreted by	vitamin-K dependence	molecular weight (kDa)	half-life (hours)	plasma concentration (mg/ml)	deficiency
factor I	fibrinogen ABg: a high-molecular-weight plasma protein which is converted to fibrin through the action of thrombin	hepatocytes	-	340	90	175-433 mg/dL = 4.0-10.0 mmol/L	afibrinogenemia or hypofibrinogenemia
factor II	prothrombin : a plasma protein that is converted to the active form thrombin (factor IIa) by cleavage by activated factor X (Xa) in the common pathway of blood coagulation; thrombin then cleaves fibrinogen to its active form fibrin prothrombin activator : any of the substances in the intrinsic or extrinsic pathways of coagulation including factors III, VII, X, and XII.	hepatocytes	+	70	60	100 (activity : 60-140%)	hypoprothrombinemia
factor III	tissue thromboplastin / tissue factor (TF) / CD142 : a lipoprotein expressed on subendothelial fibroblasts and functioning in the extrinsic pathway of blood coagulation, activating factor X	tissues	-	46	-	-
factor IV	calcium : a factor required in many phases of blood coagulation	-	-	-	-	-
factor V	proaccelerin / accelerator globulin (AcG) / labile factor : a heat- and storage-labile material, present in plasma but not in serum, functioning in both the intrinsic and extrinsic pathways of blood coagulation, catalyzing the cleavage of prothrombin to the active thrombin. When adsorbed to platelets it is called platelet factor 1 (PF1)	hepatocytes, megakaryocytes	-	330	18-25	10 (activity = 60-140%)	parahemophilia
factor VI	a factor (accelerin) previously thought to be an activated form of factor V. It is no longer considered in the scheme of hemostasis, and hence it is currently assigned neither a name nor a function	-	-	-	-	-
factor VII	proconvertin / serum prothrombin conversion accelerator (SPCA) / stable factor : a heat- and storage-stable factor participating in the extrinsic pathway of blood coagulation. It is activated by contact with calcium and in concert with factor III (tissue thromboplastin) activates factor X. The activated form is called also convertin	hepatocytes	+	48	5-6	0.13-1.00 (activity = 70-130%)	hereditary (autosomal recessive)or acquired (associated with vitamin K deficiency), results in a hemorrhagic tendency
factor VIII	antihemophilic factor (AHF) A or globulin (AHG) : a relatively storage-labile factor participating in the intrinsic pathway of blood coagulation, acting (in concert with von Willebrand factor) as a cofactor in the activation of factor X. Interactionsref :	hepatocytes, RES	-	300	10-14	0.05-0.15 (activity = 50-200%)	hemophilia A (classical hemophilia)
factor IX	plasma thromboplastin component (PTC) / autoprothrombin II / Christmas factor / antihemophilic factor B : a relatively storage-stable substance involved in the intrinsic pathway of blood coagulation; upon activation, it activates factor X	hepatocytes	+	57	20-25	5 (activity = 60-140%)	hemophilia B
factor X	autoprothrombin C / Stuart-Prower factor : a storage-stable factor that participates in both the intrinsic and extrinsic pathways of blood coagulation, uniting them to begin the common pathway of coagulation. Once activated, (factor Xa) it forms a complex with calcium, phospholipid, and factor V; the complex (prothrombinase) can cleave and activate prothrombin to thrombin. The activated form is called also thrombokinase	hepatocytes	+	59	40-60	12 (activity = 70-130%)	systemic coagulation disorder
factor XI	plasma thromboplastin antecedent (PTA) / antihemophilic factor C : a stable factor involved in the intrinsic pathway of blood coagulation; once activated (factor XIa), it activates factor IX	hepatocytes	-	160	50-65	3-6 (activity = 60-140%)	hemophilia C
factor XII	Hageman, glass, contact, or activation factor : a stable factor activated to factor XIIa by contact with glass or other foreign surfaces, which initiates the intrinsic process of blood coagulation by activating factor XI and participates in activation of the kinin and fibrinolytic pathways contact activation : initiation of the intrinsic pathway of coagulation through interaction of factor XII with various electronegative surfaces, such as collagen fibers, skin, or sebum in vivo, or particulate silicates in vitro.	hepatocytes	-	80	55-60	30 (activity = 60-140%)	thrombotic disorders, due to lack of activation of the fibrinolytic pathway
factor XIII	fibrin-stabilizing factor (FSF) / fibrinase / protransglutaminase / Laki-Lorand factor (A1 and A2 polypeptides) : a factor that polymerizes fibrin monomers so that they become stable and insoluble in urea, thus enabling fibrin to form a firm blood clot. The activated form is also called transglutaminase.	megakaryocytes, hepatocytes	-	320	90-150	10-20	hemorrhagic diathesis
Fletcher factor / prekallikrein	a plasma protein that is the proenzyme of plasma kallikreins, being cleaved and activated by activated coagulation factor XII	hepatocytes	-	86	58	50
		hepatocytes	-	120	168	70-90

•  von Willebrand's factor (vWF) : a large multimeric glycoprotein that circulates complexed to factor VIII and mediates platelet adhesion under conditions of elevated fluid shear stress, including damaged epithelia. ADAMTS-13 rapidly cleaves newly secreted ultralarge vWF multimers on the endothelial surface under flowing conditions^ref : a recombinant A2 domain protein is rapidly cleaved in the absence of both denaturant agents and divalent cations^ref and that recombinant A2 variants containing type 2A mutations of group 2 had little or no effect on proteolysis by ADAMTS13^ref. The mature polypeptide of VWF consists of 2050 amino acids, and it first dimerizes then polymerizes to generate multimers that may exceed 20 000 kDa. VWF is synthesized by megakaryocytes and endothelial cells. The latter secrete ultralarge multimers of VWF : strings formed immediately at exocytosis from endothelial cells may be anchored to the cell surface by interaction of the D'-D3 domains of VWF with the lumenal domain of the integral membrane protein P-selectin^ref. When into plasma, where they are cleaved by the metalloprotease ADAMTS13, which cleaves at a single site within the second of 3 consecutive A domains (the A2 domain), between residues Y1605 and M1606. The high-molecular-weight multimers (HMWMs) of VWF are the most active in hemostasis. This fact is supported by the naturally occurring mutations that cause von Willebrand's disease type 2A. NOTE: this factor was originally considered to be part of factor VIII, so that in older terminology the term factor VIII generally refers to the complex of the two factors. Botrocetin (bt) facilitated binding of VWF to the platelet membrane GPIb-IX-V complex on platelets in suspension initiates a signaling cascade that causes a_IIbb₃ activation and platelet aggregation. Bt/VWF-mediated agglutination activates a_IIbb₃ and elicits ATP secretion in a TxA₂-dependent manner. The signaling that results in TxA₂ production is initiated by Lyn, enhanced by Src and propagated through Syk, SLP-76, PI3K, PLC2 and PKC. The signaling elicited by GPIb- mediated agglutination that results in TxA₂ production is dependent on Btk. The results demonstrate that Btk is downstream of Lyn, Syk, SLP-76 and PI3K, upstream of ERK1/2, PLC2 and PKC, and that Btk greatly enhances Akt phosphorylation. The relationship(s), if any between ERK1/2, PLC2 and PKC were not elucidated. The requirement for Btk and TxA₂ receptor function in GPIb-dependent arterial thrombosis was confirmed in vivo by characterizing blood flow in ferric chloride treated mouse carotid arteries. The Btk family kinase, Tec, cannot provide the function(s) missing as a consequence of a Btk mutation, and that Btk is essential for both bt/vWf-mediated agglutination-induced TxA₂ production and GPIb-dependent stable arterial thrombus formation in vivo^ref.
Summary of naturally occurring ... :

		molecular weight (kDa)	plasma concentration (mg/dl)	inactivated factors	deficiency
anticoagulants	a2-macroglobulin	725	210	kallikrein, FXIIa, FXIa, FIXa, FXa, thrombin, plasmin, elastase, FXIa	none
	a1-antitrypsin	50	300	elastase, plasmin, FXIa	pulmonary emphysema, liver cirrhosis
	C1-INH	105	24	kallikrein, FXa, thrombin	angioneurotic edema
	glucosaminoglycans (GAGs) heparan sulfate
	antithrombin III / heparin cofactor I	58	19-31 (80-120%)	kallikrein, FXIIa, FXIa, FIXa, FXa, thrombin	juvenile venous thromboembolism
	heparin cofactor II / SERPIND1	66	9	thrombin	juvenile venous thromboembolism
	protein C	62	0.4	FVa, FVIIIa, endothelial cell protein C receptor (EPCR) is expressed by endothelial cells of large blood vessels and by hematopoietic stem cel	juvenile venous thromboembolism
	complement S-protein / vitronectin	69	1 (free; higher in males)	activated protein C cofactor	juvenile venous thromboembolism
	CD141 / thrombomodulin
	PGI2 / prostacyclin
	tPA
	LACI / thrombin-activatable fibrinolysis inhibitor (TFPI)	33	<= 0.01	TF/FVIIa, FXa
antifibrinolytics	a2-antiplasmin	67	7	plasmin	hyperfibrinolysis
	plasminogen activator inhibitor type 1 (PAI-1) / SERPINE1	105	24	t-PA	hyperfibrinolysis
	tissue factor (TF)
	vWF

• clot retraction time : the time required for 50% of a blood clot to retract from the wall of the vessel containing it; it is prolonged in thrombasthenia and certain other conditions
• fibrinolytic system :
• plasmin / fibrinolysin : a serine endopeptidase that catalyzes the hydrolysis of peptide bonds on the carboxyl side of lysine or arginine residues. The enzyme occurs in plasma as plasminogen, which is activated via cleavage by the plasminogen activators :
• tissue plasminogen activator (TPA / t-PA / PLAT / t-plasminogen activator) / EC 3.4.21.68 : a serine endopeptidase synthesized by endothelial cells, the major physiologic activator of plasminogen; when bound to fibrin clots it catalyzes the conversion of plasminogen to plasmin by hydrolysis of a specific arginine-valine bond. It can be produced by recombinant technology for use in therapeutic thrombolysis
• urokinase-type plasminogen activator (u-PA / PLAU) / u-plasminogen activator / EC 3.4.21.74 / urokinase : a serine endopeptidase that acts as a plasminogen activator by catalyzing the preferential cleavage of plasminogen at the same arginine-valine bond where t-plasminogen activator (t-PA) cleaves. It is produced in the kidney and excreted in the urine and has been used to induce therapeutic thrombolysis; unlike t-PA or prourokinase it does not require fibrin for activity
• single chain urokinase-type plasminogen activator (scu-PA) / prourokinase
Plasmin solubilizes fibrin clots and also degrades various proteins including fibrinogen and coagulation factors V and VII. Plasminogen is activated for therapeutic thrombolysis by recombinant forms of physiologic activators and by streptokinase, a streptococcal enzyme
Laboratory examinations :
• fibrin degradation products (FDP) (n.v. < 1 mg/l)
• euglobulin lysis test : a test that evaluates for hemorrhagic tendencies by measuring time of fibrinolysis, done by determining the time required to dissolve an incubated clot composed of precipitated plasma euglobulin and exogenous thrombin. Lysis in < 90 minutes indicates abnormally enhanced fibrinolytic activity.

 

structure	diameter [cm]	blood velocity [cm / s]	Reynold number (assuming blood viscosity = 0.035 P)
ascending aorta	2.0-3.2	63	3600-5800
descending aorta	1.6-2	27	1200-1500
large artery	0.2-0.6	20-50	110-850
capillaries	0.0005-0.001	0.05-0.1	0.0007-0.003
large veins	0.5-1.0	15-20	210-570
vena cava	2	11-16	630-900

• Fahraeus-Lindqvist effect : blood viscosity is lower in small vessels (diameter < 1.5 mm) than in large vessels, the viscosity in capillaries being less than half that in large vessels; the effect is due to red cells moving together in single file through the small vessels

• SMA 6/60 : trademark for an automated chemistry system that determines the concentrations of six substances in serum in 60 minutes and reports the results in a fixed sequence; the substances measured are creatinine or glucose, urea nitrogen, chloride, carbon dioxide, sodium, and potassium.
• SMA 12/60 : trademark for an automated chemistry system that determines the concentrations of 12 substances in serum in 60 minutes and reports the results in a fixed sequence; the substances measured are calcium, inorganic phosphorus, glucose, urea nitrogen, uric acid, cholesterol, total protein, albumin, total bilirubin, alkaline phosphatase, lactate dehydrogenase, and aspartate transaminase.
• A/G ratio
• albumin
• alkaline phosphatase
• bilirubin, total
• BUN/creatinine ratio
• calcium
• chloride
• cholesterol
• chol/HDL
• CO₂
• creatinine
• glucose
• HDL chol
• LDL/HDL Ratio
• percent HDL
• phosphate (as phosphorus)
• potassium
• SGOT (AST)
• SGPT (ALT)
• sodium
• total protein
• triglycerides
• urea nitrogen
• uric acid
• GGTP
• LDH
• iron
• globulin

• Hematology MiniCOPE Dictionary
• Hematology at Weizmann Institute
• Whole blood, serum and plasma chemistry at Weizmann Institute
• An introduction to blood groups by Gareth Page and Paul Norman

• the capillaries in most tissues are normally leaky. In a healthy adult, this results in daily leakage of 20 L of protein-poor fluid into the extravascular space. About 90% of this aqueous fluid is locally resorbed, whereas the remaining 2 L per day is returned to the circulation through lymph vessels

Copyright © 2001-2014 Daniele Focosi. All rights reserved  |  Terms of use  | Legal notices
About this site  |  Site map  |  Acknowledgements | Open forum  |    |  Current link partners
 Abbreviations and acronyms  |  Medical terminology  |  Add a link  |  Translate   |  Softwares

---